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ABSTRACT
SENECAVIRUS A: PATHOGENICITY AND INTERACTIONS WITH HOST CELL
DEATH PATHWAY
MAUREEN HOCH VIEIRA FERNANDES
2019
Senecavirus A (SVA) is a positive sense single-strand RNA virus of the genus
Senecavirus, family Picornaviridae. Senecavirus A is an emerging picornavirus of swine,
which causes vesicular disease (VD) in pigs that is clinically indistinguishable from footand-mouth disease and other high consequence VDs of swine. There is evidence that SVA
has been circulating in the US swine population since the late eighty’s, however, recently
the virus emerged worldwide, and it has been associated with several VD outbreaks in pigs
in many of the major swine producing countries. Despite the recent surge in the number of
cases of SVA, the factors underlying the emergence of SVA, as well the molecular basis
of SVA interactions with the host remain unknown. The overall goal of this study was to
improve the understanding of the SVA infection biology and its interactions with the swine
host. The objectives of our study were: 1) To compare the pathogenicity and infection
dynamics of a historical and a contemporary SVA strains (SVV 001 and SD15-26) and to
evaluate cross-reactive immune responses; and 2) To investigate the role of apoptosis on
infection and replication of SVA. To achieve the first objective, an animal study was
performed in pigs. The animals were inoculated with SVA SVV 001 or SD15-26 and the
animal were monitored for 14 days. Both SVA strains successfully infected all inoculated
animals, resulting in viremia and antibody and cellular immune responses. SVA SVV 001
did not cause overt clinical disease with inoculated animals remaining clinically normal
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during the experiment, while SVA SD15-26 infection resulted in characteristic clinical
signs and vesicular lesions. Levels of viremia detected in SVA SD15-26 inoculated animals
were significantly higher than those detected in SVA SVV 001-inoculated animals.
Differences in virus shedding were also observed mostly in nasal secretions, with SVV
001-inoculated animals shedding lower amounts of virus. Whereas similar levels of virus
shedding were observed in oral secretions and feces. Neutralization- and -recall IFN-γ
expression-assays revealed marked cross-neutralizing antibody and cross-reactive T cell
responses between the two viral strains. To achieve the second objective, we investigated
the host apoptotic responses during SVA infection and further dissected the interplay
between the virus, host cell apoptosis and NF-κB signaling. First, we demonstrated that
SVA infection induces apoptosis late during infection in vitro and in in vivo. Since NF-κB
is one of the major players modulating host cell apoptosis, we assessed its activation in
infected cells. We detected activation of NF-κB pathway early during SVA infection, while
late in infection, a cleaved product corresponding to the C-terminus of NF-κB-p65 was
observed in infected cells, resulting in lower NF-κB transcriptional activity. We showed
that expression of SVA 3Cpro was associated with cleavage of NF-κB-p65 and Poly (ADPribose) polymerase (PARP), suggesting its involvement in virus-induced apoptosis. Most
importantly, we showed that while cleavage of NF-κB-p65 is secondary to caspase
activation, the proteolytic activity of SVA 3Cpro is essential for induction of apoptosis.
Finally, we confirmed the relevance of late apoptosis for SVA infection through
experiments using a pan-caspase inhibitor, indicating that SVA-induced apoptosis is
probably involved in facilitating virus release and/or spread from infected cells. Results
from these studies provide important information on SVA infection and shed light on
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differences in biological properties and pathogenesis of contemporary and historical SVA
strains, as well as on the role of apoptosis for SVA infection biology.
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Chapter 1: Literature Review

1. Introduction
Senecavirus A (SVA), an emerging picornavirus of swine, causes vesicular disease
(VD) that is clinically indistinguishable from other swine VDs, including the highly
contagious foot-and-mouth disease (FMD) (1, 2). SVA has been circulating in the US
swine population since the late 1980s (3), however, recently the virus emerged worldwide
and it has been associated with an increased number of outbreaks in pigs in several
countries (2–11).
Despite the recent surge in the number of cases of SVA in major swine producing
countries around the world (2, 5–11), the factors underlying the emergence of the virus and
the molecular basis of SVA interactions with the swine host remain unknown. One
possibility is that the evolutionary changes that accumulated over the years on the SVA
genome led to changes in the biological properties of the virus, which might have enhanced
its fitness and virulence in the swine host. A better understanding of the biology of SVA is
critical for the development of improved control strategies and may lead to the design of
improved diagnostic tools and vaccines.
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In addition to its relevance to agriculture, SVA is also important to human health as the
virus has been used as an oncolytic agent for cancer treatment in humans (12–15). The
cytolytic potential of SVA and its selective tropism for cancer cells were determined soon
after its identification, making the virus an attractive candidate for oncolytic virotherapy
(13, 16). Several studies have shown that SVA SVV-001 kills tumor cells through
intracellular viral replication resulting in cell lysis and autophagy of infected cells in vitro
(14). Therefore, understanding the molecular interactions of SVA with host cell signaling
pathways may allow the development of novel and improved SVA-based oncolytic agents
for cancer treatment in humans.
2. Senecavirus A
2.1 Biological properties and history
Senecavirus A (SVA) is a positive-sense single-strand RNA virus, which belongs to
the genus Senecavirus, family Picornaviridae (16, 17). The SVA genome is approximately
7.2 kb in length and it contains a single open reading frame (ORF) which encodes a 2181
aa polyprotein, flanked by untranslated regions (UTRs) in both 5’ and 3’ends, with a
poly(A) tail in the 3’end, (16). The polyprotein is cleaved into four structural proteins (VP4,
VP2, VP3, and VP1) and eight non-structural proteins (L, 2A, 2B, 2C, 3A, 3B, 3C and 3D)
by the viral protease 3C (16). The VPs form the capsid of the virus that contains 60
protomers arranged in an icosahedral organization (17, 18), in which VP1, VP2, VP3 are
located on the outer surface and VP4 is located on the internal side of the capsid (17). The
spherical virus particles have approximately 27-30 nm of diameter (16).
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Senecavirus A (SVA) was first described in Maryland (USA) in 2002 as a contaminant
of cell culture (16). Based on the small size, the icosahedral appearance of the virion under
electron microscopy the virus kinetics of replication, SVA was identified as a picornavirus
and initially designated Seneca Valley virus-001 (SVV 001) (16). Later retrospective
studies conducted in archived samples at the US Department of Agriculture National
Veterinary Services Laboratory revealed that SVA had been circulating in the USA since
1988 (3). From 2002 until 2014, SVA was associated with sporadic cases of VD in pigs in
Canada and the USA (3–5). However, in November of 2014, several VD outbreaks in
which SVA was detected were reported in Brazil (1, 2). Metagenomics sequencing
performed in clinical samples collected during the outbreaks revealed the presence of SVA
(1, 2).
2.2 Epidemiology, pathogenesis and immune responses
Although SVA-specific antibodies have been reported in cattle (3) and the virus RNA
was detected in mice and house flies (7), to date the virus has only been associated with
clinical disease in pigs. SVA outbreaks presented morbidity rates ranging between 0.5 to
5% in weaned pigs, 5 to 30% in finishing pigs and breeders, and 70 to 90% in sows (1, 19,
20). Outbreaks of SVA VD have been reported in China (6), Brazil (2), the USA (7–9),
Canada (21), Thailand (10) and Colombia (11).
Senecavirus A infection likely occurs via the oronasal route, with a short incubation
period of 3 to 5 days (22, 23). The first clinical signals are lethargy and lameness, followed
by the development of vesicles on the oral mucosa, snout and feet (dewclaw, coronary
band, sole) (22, 23). The disease is usually resolved by day 14-16 post-infection (22, 23).
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In addition to VD, SVA has also been detected in cases of diarrhea and neonatal mortality,
however, the actual role and contribution of the virus to this clinical manifestation has not
yet been confirmed experimentally (24).
Senecavirus A infection results in a short-term viremia (3-10 days post-infection) (22,
23, 25) and infectious virus is excreted in feces and/or oral and nasal secretions up to 21
days post-infection (22). Viral RNA has been detected in several tissues during the acute
phase of infection (22, 25). The tonsils seem to be one of the primary sites of SVA
replication as high levels of viral RNA have been detected in this tissue during acute
infection and long-after clinical resolution of the disease (38 days p.i.) (22, 25).
Host immune responses to SVA are characterized by robust neutralizing antibody (NA)
responses early upon infection. Notably, high levels of NA are detected as early as 5 days
post-infection (22, 23) and the neutralizing activity is associated with the presence of VP2
and VP3-specific immunoglobulin M (IgM) in the serum of infected animals (23). The
cellular immune responses elicited by SVA are characterized by an early increase in the
frequencies of IFN-γ-expressing CD4+ T cells, which is followed by an increase in the
frequencies of SVA-specific IFN-γ-expressing CD8+ T cells (23). Results from these
studies have shown a correlation between neutralizing antibody levels and T cell responses
with decreased levels of viremia and disease resolutions, suggesting that both humoral and
T cell responses may play a role in the control of SVA infection (23).
3. Modulation of host cell signaling pathways by Picornaviruses
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The innate immune system is the first line of the host defense against pathogens that is
activated immediately after virus entry into the cell, in order to interfere with viral
replication and suppress viral spread (26). Furthermore, cytokines released by innate
immune cells are crucial for the activation of adaptive immunity, an antigen-specific
response (27). The recognition of viral products occurs when receptors strategically
localized in the cell surface or in endosomes in the cytoplasm, named pattern recognition
receptors (PRRs), recognize and identify molecules that are unique to microorganisms, the
Pathogen-Associated Molecular Patterns (PAMPs) (28). This leads to the activation of
important antiviral signaling pathways, including the Nuclear Factor kappa B (NF-κB) and
type I Interferon (IFN) responses, which induce an “antiviral state” restricting the spread
of infection (29). Picornaviruses have evolved several mechanisms to avoid the host
clearance by suppressing innate immune response (26).
The strategies and the targets of innate immune evasion by picornavirus are diverse.
Interestingly, several nonstructural proteins encoded by picornaviruses have been shown
to be key players in improving virus replication by targeting important host cell proteins.
The L protein of foot-and-mouth disease virus (FMDV) has been described as an inhibitor
of the NF-κB pathway (30). The 2A protein has been shown to block transcription of IFN
type I transcription in Coxsackievirus B (CVB3), Poliovirus (PV) and Enterovirus 71infected cells (EV71) (31). Additionally, the CVB3 2A has been shown to induce apoptosis
(32), while EV71 2A inhibits cellular nucleocytoplasmic transport (33). The 2C protein
also plays a role in the inhibition of the NF-κB pathway in EV71 (34, 35), while in FMDV
it has been shown to interact with N-myc and STAT interactor (Nmi) inducing apoptosis
(36). The FMDV 3A has been shown to interact with different host proteins, including
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retinoic acid-inducible gene-I (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and virus-induced signaling adaptor (VISA), resulting in inhibition of the IFN-b
pathway (37). The 3D polymerase protein of Enterovirus 68 (EV68) and EV71 has been
shown to function in modulating the host cell cycle, specifically on the progression of
G0/G1 to S phase to increase virus replication (38, 39).
3.1 Modulation of NF-κB signaling by picornaviruses
Modulation of innate immunity pathways seems to be fundamental for efficient and
productive picornavirus infection (40). Among the target innate immune signaling
pathways, the NF-κB pathway is involved in pro-inflammatory responses, innate immune
responses, and apoptosis (41). Activation of the NF-κB signaling pathway by viruses
occurs when PRRs detect PAMPs, including double-stranded RNA (dsRNA) and viral
proteins (42, 43). NF-κB is normally found as a homo or heterodimer complex formed by
Rel-like proteins (p50, p52, RelA/p65, RelB, c-Rel) (41), which is sequestered by NF-κB
inhibitor alpha proteins (NFκBIA/IκBα) in the cytoplasm of quiescent cells (44). NF-κB
activation is mediated by phosphorylation of IκBα by upstream kinases (IKKα, IKKβ)
followed by its proteasomal degradation, allowing the release of NF-κB-p65 into the
nucleus to modulate gene transcription (41). The antiviral and proinflammatory genes
stimulated by NF-κB are crucial for the first line of host defense (40). Given the critical
roles of NF-κB in inflammation, innate immune responses, and apoptosis, it is not
surprising that many picornaviruses have evolved to inhibit the NF-κB signaling pathway.
Among the picornaviruses, PV has been shown to suppress the NF-κB pathway through
cleavage of NF-κB-p65 by the viral 3Cpro (45). The 3Cpro of CVB3 also inhibits NF-κB
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during infection by cleaving IκBα, which then forms a stable complex with NF-κB-p65,
avoiding the activation of NF-κB-regulated genes (46). FMDV utilizes one of its proteases,
Lpro, to cleave NF-κB-p65 (30). EV71 2C binds to NF-κB-p65 to suppress its activity (34).
Additionally, EV71 2C inhibits the phosphorylation of IKKβ, avoiding the release of NFκB-p65 into the nucleus to regulate gene transcription. Differently from these
picornaviruses, EMCV seems to stimulate the NF-κB pathway, resulting in increased
expression of pro-survival genes (47).
3.2 Modulation of cell death or apoptotic pathways by picornaviruses
Another important cellular process related to innate immunity that is modulated by
several picornaviruses and presents a crossover with the NF-κB pathway discussed above,
is programmed cell death, or apoptosis. Activation of apoptosis occurs mainly by two
distinct pathways, the intrinsic and extrinsic apoptotic pathways, which utilize cellular
caspases as executioners (48, 49). The intrinsic pathway involves the mitochondria and is
initiated by several stress signals, including oxidative stress, DNA damage and growth
factor deprivation (49). The extrinsic pathway involves the cell surface death receptors,
which belong to the tumor necrosis factor receptor (TNFR) gene superfamily (50). Tumor
necrosis factor-alpha (TNF-α) is a death-inducing cytokine secreted during viral infections
that activates apoptosis through TNFR1 signaling (51). Besides its role in cell death, TNFα also functions in cell survival by stimulating the activation of the NF-κB pathway, which
modulates the transcription of pro-inflammatory- and pro-survival genes (52). After the
apoptotic pathway is activated, the caspases modulate cellular changes that characterize
this process, such as disassembling of the nuclear membrane and the blade framework,
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chromatin hyper condensation and DNA degradation, nuclear and cytoplasmic
disintegration, and then the formation of apoptotic vesicles (48, 49). Unlike necrosis, there
is no release of the cellular content into the interstitial tissue, since all the debris is inside
the apoptotic vesicles, which are quickly phagocytosed by macrophages or adjacent normal
cells, and therefore there is no inflammation around the cells that die by apoptosis (53).
Some picornaviruses are known to induce apoptosis, including EV71 (54–56), CVB3
(32, 57, 58), Hepatitis A virus (HAV) (59–61) and FMDV (62), however, the exact
mechanism(s) underlying this function remains unclear for several of these viruses. During
EV71 infection, two of its proteases, 2Apro and 3Cpro, induce apoptosis by cleavage of the
eukaryotic initiation factor 4GI (a key factor for host protein synthesis) and cleavage of
cellular protein PinX1 (a telomere binding protein), respectively (54, 56). The production
of Nox4-dependent ROS is involved in CVB3 induced myocardial apoptosis (57), while in
HeLa cells, both CVB3 2Apro and 3Cpro promote apoptosis by mitochondrial injury and
cleavage of eukaryotic translation initiation factor 4GI (32). The 3Cpro of HAV induces
vacuolization of lysosomal/endosomal organelles and caspase-independent cell death (38).
It has been reported that HAV-induced apoptosis might facilitate virus replication as it has
been associated with higher virus titers in host tissues (60). During FMDV infection the
presence of apoptotic cells was detected in the vesicular lesions induced by the virus on
the tongue of infected pigs (62). Notably, PV modulates the apoptosis pathway by either
activating or suppressing its induction (63, 64). Activation of the apoptotic pathway seems
to be related to calcium flux from the endoplasmic reticulum, causing the release of
cytochrome c from the mitochondria (63, 64). PV-induced suppression of apoptosis
appears to occur as negative feedback of mitochondrial cytochrome c release, causing
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overexpression of BCL-2 and aberrant processing and degradation of procaspase-9 (64).
These observations suggest a complex interaction of picornaviruses with host cell death
pathways.

4. 3C Protease
4.1 Structure and mechanism of action
The picornaviral 3Cpro has a cysteine nucleophile combined with a trypsin-like protease
fold (65). Its catalytic triad is generally formed by a His-Glu/Asp-Cys in the center of its
structure (66, 67). The putative catalytic triad of SVA strain SD15-26 from South Dakota
3Cpro consists of histidine 47 (H47), aspartate 83 (D83) and cysteine 159 (C159). This
active site, known as peptide-binding cleft, is located at the interface between two β-barrels
(67), which is characteristic of serine proteases (68). Prior to binding of the 3Cpro to a
substrate, the protease undergoes a conformational change, in which the β-ribbon (a
flexible surface loop observed in several picornaviral 3Cpro) opens its conformation to
increase the accessibility to the substrate, then once bound, the β-ribbon and the N-terminal
portion of the substrate stabilize and form the enzyme-substrate complex (69). The
specificity for the substrate depends on amino acid sequences in the target proteins and the
cleavage site of the protease. Picornavirus 3Cpro cleavage usually occurs on Q-G residues
present in the target proteins (70).
Each amino acid in the 3Cpro triad has a specific role in the chemical reaction that
cleaves target proteins, between Q-G residues. The cysteine has an -SH group that acts as
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a nucleophile, attacking the carbonyl carbon of the scissile peptide bond of the substrate.
While, a pair of electrons on the histidine nitrogen accepts the hydrogen from the cysteine
-SH group, thus coordinating the cleavage of the peptide bond. At the same time, the
carboxyl group on the aspartate form hydrogen bonds with the histidine, making the
nitrogen atom of histidine more electronegative (68).
4.2 Host protein interactions
The picornavirus 3Cpro is essential for viral replication not just for being responsible
for the processing of the viral polyprotein, but also for its involvement in viral pathogenesis
due to its interactions with many host proteins (69). Proteins of the innate immune system
seem to be major targets of 3Cpro. For example, FMDV 3Cpro cleaves an essential modulator
of innate immunity, NEMO, inhibiting IFN type I response (71). EV68 3Cpro cleaves
interferon regulatory factor 7 (IRF7) (72) and the TIR domain-containing adaptor inducing
beta interferon (TRIF) (73), which reduces significantly the activation of type I IFN and
IFNβ, respectively. SVA 3Cpro also is described as a mediator of IFN production, by
cleaving Mitochondrial antiviral-signaling protein (MAVS), TRIF, and TRAF Family
Member-associated NF-κB Activator (TANK) (74). Another target is the NF-κB, in which
PV 3Cpro cleaves NF-κB-p65 to avoid its activation (45). CVB3 3Cpro is able to cleave
IκBα, allowing the formation of a stable complex with NF-κB-p65, preventing the
expression of NF-κB inducible genes (46). Differently, EMCV 3Cpro cleaves TANK,
allowing its release and resulting in activation of the NF-κB signaling pathway (75).
Additionally, the 3Cpro of several picornaviruses has been shown to modulate cell death
pathways through different mechanisms (32, 54, 56, 61, 76). For example, CVB3 3Cpro
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promotes apoptosis by mitochondrial injury and cleavage of eukaryotic translation
initiation factor 4GI (32). HAV 3Cpro induces apoptosis in a caspase-independent way and
induces vacuolization of lysosomal/endosomal organelles (61). Distinctively, EV71 3Cpro
activates the apoptotic pathway by cleavage of the eukaryotic initiation factor 4GI and the
cellular protein PinX1 (54, 56). PV 3Cpro is also described as an apoptosis inducer,
however, the precise mechanism of action is unknown (76). Another consequence of
picornavirus 3Cpro expression is the disruption of cellular transport (77, 78). This occurs as
a consequence of Human rhinovirus (HRV) 3Cpro function, which facilitates specific
nucleoporin cleavage and mislocalization of nuclear proteins in infected host cells (77);
and the FMDV 3Cpro promotes the fragmentation of early, medial, and late Golgi
compartments (78).
Objectives
The overall goal of this project was to improve the understanding of the infection
biology of SVA and its interactions with the swine host. The objectives of our study were:
Objective 1: To compare the pathogenicity and infection dynamics of a historical and a
contemporary SVA strains (SVV 001 and SD15-26) and to evaluate cross-reactive immune
responses.
To achieve this objective an animal study was performed in pigs. The animals were
inoculated with SVV 001 or SD15-26 strains and the animal were monitored for 14 days.
Clinical signals and biological samples were collected to compare the pathogenicity and
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infection dynamics of both strains, well as cross-reactive immune responses. The results of
this study are presented in Chapter 2 of this dissertation.
Objective 2: To investigate the role of apoptosis on infection and replication of SVA.
To achieve this objective, we investigated the host apoptotic responses to SVA
infection and we dissected the interplay between the virus, host cell apoptosis, and NF-κB
signaling. The results of this study are presented in Chapter 3 of this dissertation.
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ABSTRACT
The goals of this study were to compare the pathogenicity and infection dynamics
of a historical and a contemporary SVA strains (SVV 001 and SD15-26) and to assess
cross-neutralizing and cross-reactive T cell responses following experimental infection in
pigs. Both SVA strains successfully infected all inoculated animals, resulting in viremia
and robust antibody and cellular immune responses. SVA SD15-26 infection resulted in
characteristic clinical signs and vesicular lesions, however, SVA SVV 001 did not cause
overt clinical disease with inoculated animals remaining clinically normal during the
experiment. Notably, neutralization- and -recall IFN-γ expression-assays revealed marked
cross-neutralizing antibody and cross-reactive T cell responses between the two viral
strains. Together these results demonstrate that the historical SVA SVV 001 strain presents
low virulence in pigs when compared to the contemporary SVA SD15-26 strain.
Additionally, immunological assays indicate that SVA SVV 001 and SD15-26 are
antigenically related and share conserved antigenic determinants.

Key words: Senecavirus A, Seneca Valley virus, Pathogenesis, Vesicular disease, Crossimmunity.
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Introduction
Senecavirus A (SVA) is a non-enveloped, single-stranded positive sense RNA virus, which
belongs to the genus Senecavirus family Picornaviridae (79). The SVA genome is ~ 7.2 kb
in length and contains a single open reading frame (ORF) flanked by untranslated regions
(UTRs) in the 5′ and 3′ ends, with a poly(A) tail at the 3′ end of the genome (16). The ORF
is translated in a large polyprotein (2181 aa) that is cleaved by 3Cpro, a viral encoded
protease, into 12 viral proteins (5′–L–VP4–VP2–VP3–VP1–2A–2B–2C–3A–3B–3C–3D3′) (16). The VPs form the capsid that consists of an icosahedral arrangement of 60
protomers, each composed by VP1, VP2, VP3 and VP4 (17, 18). The remaining
polypeptides are nonstructural proteins that function on virus replication (80) and may play
important roles on virus virulence and pathogenesis (16, 80).
Senecavirus A was isolated for the first time in the United States (US) in 2002 as a
contaminant of PER.C6 cell cultures (16). Electron microscopy performed on infected cells
revealed icosahedral viral particles of about 27 nm in diameter. Based on the size and
morphology of the virion, replication kinetics, and genomic sequences, the newly
discovered virus was identified as a novel picornavirus and designated Seneca Valley virus
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(SVV), with the isolate being named SVV 001 (16). Recently, SVV was renamed and is
currently known as Senecavirus A (SVA), with SVV 001 being the prototypic SVA strain
(81). Following SVA SVV 001 discovery in 2002, a seroepidemiologic study detected
antibodies against the virus in pigs and other animal species in the US (3). Additionally,
screening of archived swine samples using molecular assays and sequencing confirmed the
circulation of SVA in the US swine population since 1988 (3). From 2002 until 2014, SVA
was only associated with few cases of vesicular disease in pigs in Canada and in the US
(3–5). Late in 2014, several outbreaks of vesicular disease (VD) in pigs, resembling footand-mouth disease (FMD), and characterized by the development of vesicles on the snout
and coronary bands of affected animals were reported in Brazil (1, 2). The virus detected
during these outbreaks shared 94.2% nucleotide identity with SVA SVV 001 (2). Since the
detection of SVA in Brazil in 2014, the virus has been associated with various outbreaks
of VD in other countries, including China (6), the US (7–9), Thailand (10) and Colombia
(11). Notably, since its re-emergence in the US, in July 2015, more than 300 cases of SVA
have been confirmed (82). The factors underlying the emergence of SVA and the increase
in disease incidence remain largely unknown. Interestingly, genetic comparisons between
historical- (obtained prior to 2006) and contemporary SVA isolates (obtained between
2007 and 2015) revealed a marked genetic divergence and evolution of contemporary SVA
isolates (7). Whether these genetic changes contributed to an increase in virulence and
pathogenicity of contemporary SVA strains, however, remains unknown.
The role of SVA on the etiology of VD in pigs was recently demonstrated (22, 83) and its
pathogenesis and the host immune responses to infection were studied in detail in finishing
pigs (22, 23). After a short incubation period (3–5 days post-infection [pi]), animals present
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lethargy and lameness (22, 23). The clinical phase is also characterized by the development
of vesicles on the snout and/or feet (dewclaw, coronary band, and/or sole) of affected
animals. With the progression of the disease, the vesicles rupture, leaving ulcered lesions
on the skin, that eventually resolve by day 14-16 pi (22, 23). A short-term viremia (3–10
days pi) is detected and infected animals develop early neutralizing antibody (NA)
responses (22, 23). Early cellular immune responses to SVA are characterized by increased
frequencies of IFN-γ-expressing CD4+ T cells, while later cell mediated responses involve
increased frequencies of SVA-specific IFN-γ-expressing CD8+ T cells (23). Virus
shedding in oral and nasal secretions and feces are detected up to 21–28 days pi (22).
Here we compared the pathogenicity of the historical SVA strain SVV 001 with a virulent
contemporary SVA strain SD15-26. The goals of the study were to assess the infection
dynamics and pathogenicity of these two strains in susceptible pigs as well as to assess
cross-neutralizing and cross-reactive T cell responses following infection.
Results
Genetic comparison between SVA strains SVV 001 and SD15-26
Complete genome sequence comparisons between SVA SVV 001 and SD15-26 showed
that these viral strains share 93.8% nucleotide identity (id) (Table 1), whereas comparison
of SVA SD15-26 with other contemporary strains revealed 96–98% nucleotide id (data not
shown). Pairwise comparisons of the ORF1 region showed 93.9% nucleotide identity
between SVA SVV 001 and SD15-26. Additionally, 94.6% and 95.6% nucleotide id was
observed when nucleotide sequences of the 5′- or 3′ UTRs were compared (Table 1).
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Pairwise comparisons of the polyprotein sequences revealed 97.8% amino acid similarity
between SVV 001 and SD15-26. A total of 49 aa substitutions are present in the ORF of
SVA SD15-26 when compared to SVA SVV 001 (Table 1). Among the capsid proteins,
VP3 presents the greatest variability (7.4%; 95.8% aa similarity), while VP4 is the most
conserved VP (100% identity) (Table 1). Several amino acid substitutions were also
observed in the non-structural proteins (Table 1), with 2A and 3A being the most variable
proteins, while 3B and 3D are the most conserved non-structural proteins (Table 1). These
results suggest a marked genetic divergence and evolution of the contemporary SVA strain
(SD15-26) when compared to the historical prototypic SVA strain SVV 001.
Infection of pigs with SVA SD15-26, but not with SVA SVV 001, results in vesicular
disease
The pathogenicity and infection dynamics of the historical SVV 001 and contemporary
SD15-26 SVA strains were compared in pigs. For this, twelve SVA-negative finishing pigs
(~60 kg), were inoculated oronasally with SVV 001 (n = 6) or SVA SD15–26 (n = 6) strains
(5 mL orally and 5 mL intranasally [half into each nostril]; titer 107.5 TCID50 mL−1) (22),
and monitored for clinical signs and vesicular lesions for 14 days. One animal from each
group was euthanized on days 3 and 7 post-inoculation (pi). All pigs inoculated with SVA
SD15-26 (5), except the animal euthanized on day 3 pi, presented characteristic clinical
signs of SVA, including lameness, lethargy and/or snout irritation. In contrast to the clinical
presentation observed in SVA SD15-26-inoculated animals, none of the animals inoculated
with the historical SVA strain SVV 001 presented clinical signs. Vesicular lesions were
observed on the feet and/or snout of SVA SD15-26-inoculated animals starting on day 4 pi
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(two out of six animals). All SVA SD15-26-inoculated animals developed characteristic
vesicular lesions on the snout and/or on the feet, with lesions being observed on the
coronary band, sole, dewclaw, and/or interdigital space (Fig. 1A). Vesicular lesions
evolved through the stages of erythema, fluid-filled vesicles, ruptured vesicles, skin
ulcers/erosions, to scabby lesions and finally normal skin. Notably, no lesions were
observed in SVV 001-inoculated pigs (Fig. 1B). Clinical scores were calculated by
attributing one point (1) to the snout and each foot (right front, left front, right hind and left
hind) presenting lesions on any day of the 14-day experiment (maximum score is 5 per
animal per day). A score of zero (0) was attributed to areas (snout or foot) presenting no
lesions. Peak clinical scores for SVA SD15-26-inoculated animals were observed on day
7 pi, when one animal with a score of 5 was euthanized. After day 7 pi, the lesions on the
snout started to subside, while scabby lesions were still observed on the feet of several
animals at the end of the experiment on day 14 pi (Fig. 1C). As no gross lesions were
observed in SVV 001-inoculated animals, clinical scores for this group remained 0
throughout the experiment (Fig. 1C). The identity of the SVA strain detected in inoculated
animals was confirmed by sequencing of a fragment of the P1 region, amplified from the
tonsil of infected animals (data not shown).
Skin samples collected from SVA SD15-26 and SVV 001-inoculated animals on days 3,
and 7 pi were subjected to histological examination. Histological changes observed on a
snout lesion of a SVA SD15-26-inoculated animal, revealed vesiculopustular dermatitis
characterized

by

vesicles containing eosinophilic homogenous fluid (edema),

accumulation of fibrin and necrotic debris (Fig. 2A). Additionally, large pustules
presenting aggregates of neutrophils admixed with variable amounts of eosinophilic
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material, cellular and karyorrhectic debris and bacteria (lytic necrosis) were also observed
(Fig. 2A). The lesions on the coronary band of SVA SD15-26-inoculated animals consisted
vesiculopustular dermatitis, characterized by mild, multifocal infiltration of inflammatory
cells composed of lymphocytes and plasma cells surrounding blood vessels in the dermis
(Fig. 2B). Consistent with the absence of gross vesicular lesions in SVV 001-inoculated
animals, no histological changes were observed on the skin of the snout and coronary bands
of animals from this group (Fig. 2C and D).
Comparative viremia levels and virus shedding
The levels of viremia in SVA SVV 001- and SVA SD15-26-inoculated animals were
assessed in serum. Serum samples collected on days 0, 1, 3, 7, 10 and 14 pi were tested for
the presence of SVA RNA using RT-qPCR. SVA was first detected in serum on day 1 pi,
with peak SVA SD15-26 viremia levels being detected on day 3 pi (Fig. 3A). On day 10
pi, only one SVA SD15-26-inoculated animal was still viremic, and on day 14 pi viral RNA
was not detected in any inoculated animal (Fig. 3A). SVA SVV 001 genome was first
detected in serum of two animals on day 3 pi and similar to the results in SVA SD15-26inoculated animals, SVA SVV 001 viremia was detected until day 10 pi (Fig. 3A). It is
important to note that, not all inoculated animals presented viremia (Fig. 3A), with a higher
frequency of viremic animals being detected in SVA SD15-26-inoculated group. Notably,
the levels of viremia detected in SVA SD15-26 inoculated animals were significantly
higher than those detected in SVA SVV 001-inoculated animals (Fig. 3A).
Virus shedding was assessed in oral and nasal secretions and feces of SVA SD15-26 and
SVV 001-inoculated animals. Oral, nasal and rectal swabs collected on days 0, 1, 3, 7, 10
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and 14 pi were subjected to RT-qPCR. Virus shedding was detected until the end of the
experiment on day 14 pi in animals from both groups (Fig. 3B, C and D). Peak viral
shedding on oral and nasal secretions and feces was detected on day 3 pi in animals from
both SVA SD15-26 and SVV 001-inoculated groups (Fig. 3B). Interestingly, while levels
of virus shedding in oral secretions and feces were similar between both groups,
significantly higher amounts of SVA RNA were detected on nasal swabs of SVA SD1526-inoculated animals when compared to SVA SVV 001-inoculated animals (Fig. 3C). No
differences in virus shedding in feces were observed between SVA SD15-26 and SVV 001
inoculated animals throughout the 14-day experimental period (Fig. 3D).
Detection of SVA RNA in non-lymphoid tissues
Viral load and tissue distribution of SVA SVV 001 and SD15-26 were assessed in nonlymphoid tissues. Tissues including heart, lungs, kidney, liver, small intestine and large
intestine were collected on days 3, 7, and 14 pi and processed for RT-qPCR. Viral load
detected in each tissue is presented in Fig. 4. Lungs and large intestine were the tissues in
which a greater number of animals from both groups were positive for SVA RNA (Fig. 4B
and F). In general, SVA SD15-26-inoculated animals present higher amounts of viral RNA
in these tissues when compared to SVV 001-inoculated animals, which corroborates the
levels of viremia detected in animals inoculated with this viral strain (Fig. 4).
Detection of SVA RNA in lymphoid tissues
Viral load was also investigated in lymphoid tissues using RT-qPCR. Viral load detected
in the thymus, spleen, mediastinal and mesenteric lymph nodes and tonsil are presented in
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Fig. 5. Notably, while SVA RNA was detected in at least one animal in all examined tissues
(Fig. 5), the tonsil was the tissue that presented the highest viral load and the highest
number of positive animals with all SVA SD15-26 and SVV 001-inoculated animals being
positive for SVA RNA throughout the experiment (days 3, 7, and 14 pi) (Fig. 5E). In
contrast, thymus was the tissue with the lowest number of positive animals, with only one
animal from the SVA SD15-26-inoculated group being positive on day 7 pi (Fig. 5A).
There was an increase in the number of animals that were positive for SVA in lymphoid
tissues with the progression of the infection, as evidenced by a higher number of positive
animals in both SVA SD15-26 and SVV 001-inoculated groups (Fig. 5). Together these
results suggest that lymphoid tissues may represent active sites of SVA replication during
the acute phase of infection. Additionally, early detection of SVA in the tonsil in both SVA
SD15-26 and SVV 001 strengthen the hypothesis that the tonsil may be the primary site of
SVA replication.
Cross-neutralization between SVA SVV 001 and SD15-26
The serological responses to both SVA strains, SVV 001 and SD15-26, were evaluated by
virus neutralization assay (VN). All inoculated animals seroconverted and presented high
levels of neutralizing antibodies (NA) on day 5 pi (Fig. 6A and B). Peak NA titers for both
groups were observed on day 10 pi (Fig. 6A and B). Notably, marked cross-neutralization
between SVA SVV 001 and SD15-26 was observed when serum from one group of animals
was used in VN assays against the heterologous strain of virus (Fig. 6A and B).
Interestingly, even when SVA SVV 001 was the virus used on VN assay, the NA titers in
SVA SD15-26-inoculated animals were higher (Fig. 6A; **p < 0.05, ***p < 0.01). These
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results confirmed successful infection of both SVA SD15-26 and SVV 001-inoculated
animals and demonstrate significant cross-neutralization between the historical and
contemporary SVA strains.
Cross-reactive T cell responses between SVA SVV 001 and SD15-26
Cellular responses to SVA SVV 001 and SVA SD15-26 were evaluated by flow cytometry
(Fig. 7). Peripheral blood mononuclear cells from SVA SVV 001 or SVA SD15-26 were
stimulated with either SVA strain and IFN-γ expression by T cells (total CD3+), and
individual T cells subsets, including CD4+, CD4+CD8+, and CD8+ T cells were
investigated on days 0 and 14 pi. Animals inoculated with either SVA strain (SVA SVV
001 or SD15-26) presented antigen-specific IFN-γ expression by T cells on day 14 pi (Fig.
7A-G). Although recall IFN-γ expression by SVA SD15-26-inoculated animals (Fig. 7I)
were slightly higher than by SVA SVV 001-inoculated animals (Fig. 7H), no statistical
differences were detected between the two groups (p > 0.05). Substantial T cell crossreactivity between SVA SD15-26 and SVV 001 was observed. The frequency of IFN-γexpression T cells in SVA SVV 001 inoculated animals were similar upon recall
stimulation with SVA SVV 001 (Fig. 7H, left panel) or SVA SD15-26 (Fig. 7H, right
panel). A similar phenotype was observed in SVA SD15-26-inoculated animals (Fig. 7I).
These results indicate that SVA SVV 001 and SD15-26 may share relevant T cells epitopes.
Discussion
In the present study, we compared the pathogenicity and infection dynamics of a historical
(SVV 001) and a contemporary (SD15-26) SVA strains in finishing pigs. Senecavirus A
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strain SVV 001 was isolated in PER.C6 cell cultures (16), presumably originating from
porcine trypsin (3). Whereas SVA SD15-26, a virulent SVA strain, was isolated from a
vesicular lesion during an outbreak of VD in the US, in 2015 (22). Results here show that
oronasal inoculation of finishing pigs with both SVA strains resulted in infection of all
inoculated animals, however, only SVA SD15-26-infection led to overt clinical disease,
while SVA SVV 001-inoculated animals remained clinically normal for the duration of the
experiment. These observations indicate that SVA SVV 001 presents low virulence in pigs.
Genetic determinants of picornavirus virulence and pathogenicity have been identified in
both coding and non-coding regions of the genome (84–86), and even silent nucleotide
changes may lead to altered virulence phenotypes (84). Nucleotide changes in coding and
non-coding regions may alter secondary RNA structures that contribute to virus replication
(87, 88), and amino acid substitutions in individual viral proteins may result in altered
protein functions, thus potentially leading to a distinct fitness of the virus in the host. In
comparison to SVA SVV 001, the contemporary SVA strain SD15-26 presents multiple
nucleotide changes involving the 5′- and 3′ UTRs and the long polyprotein-encoding ORF.
The role and contribution of the genetic changes observed in contemporary SVA strains
for the virus virulence and pathogenesis remain unknown. However, given the extent and
distribution of these changes (involving non-coding and coding regions), it is likely that
they contributed, at least in part, for the emergence of virulent contemporary SVA strains.
Both SVA SVV 001 and SD15-26 strains successfully established infection in all
inoculated animals, however, marked differences in the pathogenicity and infection
dynamics were observed. Notably, while all SVA SD15-26 inoculated pigs developed
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characteristic VD, none of the animals inoculated with SVA SVV 001 presented clinical
signs nor lesions. These observations indicate that SVA SVV 001 is less pathogenic than
SVA SD15-26 to pigs, corroborating the findings of previous pathogenesis studies
conducted with other historical SVA strains (3, 89), in which inoculated animals did not
develop clinical VD. It is important to note, however, that in the study by Yang and
collaborators, inoculation was performed through injection of SVA directly in the coronary
bands or tongue of experimental animals (89). This represents an important difference from
the inoculation route used here and it may explain the failure of the isolate used in Yang's
study to induce VD in inoculated pigs. Here, SVA SVV 001-inoculated animals also
presented delayed viremia (day 3 vs day 1) with lower levels of viral RNA being detected
in serum throughout the 14-day experiment. Differences in virus shedding were observed
mostly in nasal secretions, with SVV 001-inoculated animals shedding lower amounts of
virus. Whereas similar levels of virus shedding were observed in oral secretions and feces.
Consistent with this, the number of positive animals and the viral load in non-lymphoid
tissues were slightly lower in SVV 001 inoculated animals. Together these results indicate
that SVA SVV 001 presents a lower virulence when compared to SVA SD15-26,
reinforcing the idea that historical SVA strains may be less pathogenic to pigs. The
possibility that other historical SVA strains are virulent and capable of inducing VD in
pigs, however, cannot be formally excluded.
Previously we have shown that SVA SD15-26 appears to have tropism for lymphoid
tissues, with the tonsil being one of the target tissues during the first seven days of infection
(22). Results here corroborate with these observations, demonstrating the presence of high
amounts of viral RNA in the tonsil of both SVA SVV 001- and SD15-26-inoculated
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animals. Interestingly, when compared to the other lymphoid tissues tested (thymus,
spleen, mediastinal and mesenteric lymph nodes) the tonsil was the only tissue in which
both viral strains were detected in all animals throughout the experiment. These results
provide evidence of the importance of the tonsil as a replication site for SVA and further
suggest that this organ may be the primary site of SVA replication.
Given the great genetic and antigenic diversity of picornaviruses (90), and the nucleotide
and inferred amino acid divergence between the historical (SVV 001) and the
contemporary (SD15-26) SVA strains used here, we sought to assess cross-reactive
immune responses elicited in infected animals. Since NA are one of the most important
correlates of protection against picornaviruses (91, 92), and provide the basis for the
classification of picornaviruses into serotypes (93), we initially assessed cross-NA
responses in SVA SVV 001 and SD15-26-inoculated animals. For this, virus-specific
antisera were used in VN assays against the homologous or heterologous virus strain.
Results of these assays revealed marked cross-neutralization activity between the two SVA
strains, with NA titers in SVA SD15-26 being slightly higher (1–2-fold) than in SVA SVV
001-inoculated animals. Notably, it has been previously shown that SVA SVV 001 is also
serologically related and presents cross-neutralizing activity with several other historical
SVA isolates obtained in the US between 1988 and 2001 (3). These observations indicate
that historical and contemporary SVA strains are serologically related suggesting that these
strains share conserved antigenic determinants including neutralizing epitopes, despite the
amino acid changes present in the capsid proteins.
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Recently, we have shown that T cell responses to SVA infection are characterized by
increased frequencies of CD4+, CD8+ and double positive CD4+CD8+ T cells (23).
Picornavirus-specific T cells have been shown to recognize and respond to conserved as
well as serotype-specific T cell epitopes (94). To define cross-reactive T cell responses
between SVA SVV 001 and SD15–26, PBMCs collected from infected animals were
stimulated in vitro with each viral strain and recall IFN-γ expression was assessed by flow
cytometry analysis. Results from these experiments demonstrate significant cross-reactive
T cell responses between the two viral strains, as evidenced by increased frequencies of
IFN-γ-expressing CD3+CD4+- and CD3+CD8+ T cells following recall stimulation in
vitro. These findings corroborate the notion of conserved picornavirus T cell epitopes that
are cross-reactive between different strains- or even different species of picornaviruses (95,
96).
In summary, this study shows that there are pronounced differences in the pathogenicity
and infection dynamics between the historical prototypic SVA strain SVV 001 and the
contemporary SVA SD15-26 strain in pigs. These biological differences in the natural host
species of the virus might reflect the evolution of SVA or perhaps its enhanced fitness in
the host. Understanding differences in biological properties and pathogenesis of SVA is
critical for the development of improved diagnostic tools and vaccines for prevention and
control of this important emerging virus of swine.
Methods
Cells and viruses
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NCI-H1299 human cells were purchased from the American Type Culture Collection
(ATCC-CRL 5803). Cells were maintained at 37 °C with 5% CO2 in RPMI-1640 medium
(Corning) supplemented with 10% fetal bovine serum and 2 mM L-Glutamine. Penicillin
(100 U mL−1), streptomycin (100 µg mL−1) and gentamycin (50 µg mL−1) were also added
to the cell culture media.
Senecavirus A strain SVV 001 (purchased from ATCC - Seneca Valley virus lot 3, July
22, 2003) was the first SVA strain isolated in PER.C6 cells in 2002 (16). SVA strain SD1526 was isolated from swine presenting vesicular disease and has been fully characterized
in our laboratory (22, 23). Stocks of both SVA SVV 001 and SD15-26 strains were
prepared and titrated in H1299 cells.
Sequence analysis
Pairwise nucleotide and amino acid sequence identities between SVA SVV 001 (GenBank
accession number NC_011349) and SVA SD15-26 (GenBank accession number
KX778101) were determined with the EMBOSS Needle sequence alignment tool
(https://www.ebi.ac.uk/Tools/psa/).
Animal studies
The pathogenicity of SVA SVV 001 and -SD15-26 were compared in 15-week-old
finishing pigs. For this, 12 SVA negative finishing pigs (weighing ~ 60 kg) were randomly
allocated in two experimental groups: Group 1, SVV 001-inoculated group (n = 6), and
Group 2, SD15-26-inoculated group (n = 6). Animals from both groups were inoculated
with virus suspensions containing 107.5 TCID50 mL−1 via the oronasal route (5 mL orally
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and 5 mL intranasally [half into each nostril]). Animals were challenged on arrival at SDSU
Animal Resource Wing (ARW). Group 1 and 2 animals were maintained in separate rooms
and strict biosecurity protocols were followed, to avoid cross contamination. Animals
received food and water ad libitum for the duration of the 14-day experiment. As day 0
samples were used for baseline immune (antibody levels and T cell responses) assessments,
a control mock-inoculated group was not included in the study.
Following virus inoculation, animals were monitored daily for characteristic SVA clinical
signs and lesions. Clinical signs and lesions were recorded, and individual daily lesion
scores were attributed to each animal. A score of 1, was attributed to lesions observed on
the snout and/or each foot for a total score of 5 per animal per day (snout = 1; right front
foot = 1; left front foot = 1, right rear foot = 1; and left rear foot = 1). A score of 0, was
attributed to the snout and/or foot of each animal that did not present vesicles in any given
day of the 14-day experiment. Average daily lesion scores were calculated for each group.
Swabs (oral, nasal and rectal/fecal) and blood samples (serum and whole heparinized
blood) were collected on days 0, 1, 3, 5, 7, 10 and 14 pi. Serum and PBMCs were collected
and stored as previously described (22, 23). One animal of each group was euthanized on
days 3 and 7 pi, and all the remaining animals were euthanized on day 14 pi. Tissues (heart,
lungs, kidney, liver, small intestine, large intestine, thymus, spleen, mediastinal lymph
node, mesenteric lymph node and tonsil) were collected and stored at − 80 °C or fixed in
10% formalin. To ensure that no cross contamination occurred during the experiment,
sequencing of a fragment of P1 protein of SVA present in the tonsil of all animals was
performed. Animal experiments were revised and approved by the SDSU Institutional
Animal Care and Use Committee (approval number 16-002A).
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Viral RNA extraction and real-time RT-PCR (RT-qPCR)
Nucleic acid was extracted from serum, swabs and tissue samples using the MagMax viral
RNA/DNA isolation kit (Thermo Fisher). One gram of each tissue was minced using a
sterile scalpel, re-suspended in RPMI 1640 medium (10% w/v) and homogenized using a
stomacher (two cycles of 60 s). Homogenized tissue samples were cleared by
centrifugation and 50 µL of cleared tissue homogenate was used for nucleic acid extraction
using the automated KingFisher Flex Purification System (Thermo Scientific). Swab
samples were vortexed cleared by centrifugation and 50 µL of cleared sample used for
nucleic acid extraction as above. Fifty µL of serum were also used for nucleic acid
extraction. The presence of SVA RNA in serum, oral and nasal secretions, feces and tissues
were assessed using commercial SVA RT-qPCR reagents targeting a conserved region
within the SVA 3D polymerase (EZ-SVA TC-9079-192 Tetracore Inc.). It is important to
note that the 3D sequences targeted by the qPCR primers and probes included in the EZSVA TC-9079-192 assay are conserved between SVA SVV001 and SD15-26. A standard
curve was generated with in vitro transcribed SVA RNA and viral loads were determined
using the four-parameter logistic regression model function within MasterPlex 2010
software (Hitachi Software Engineering America, Ltd., San Francisco, CA).
Cross-neutralization assays
Neutralizing antibodies elicited by infection with SVA SVV 001 or SD15-26 were
determined by virus neutralizing antibody assays as previously described (22). To
determine the cross-neutralization levels of SVV 001 and SD15–26 serum samples from
inoculated animals were tested against both viral strains in the VN assays. NA titers were
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expressed as the reciprocal of the highest serum dilution capable of completely inhibiting
SVA infection/account inhibit replication. All assays were performed in triplicate and
positive and negative control serum samples were included in all test plates.
Flow cytometry
Intracellular IFN-γ expression assays were performed as previously described (23). SVAspecific T cell phenotypes were determined using a panel of swine-specific antibodies,
including mouse anti-pig CD3-Alexa Fluor 647 (ɛ chain specific; clone BB23-8E6-8C8,
isotype IgG2a; BD Pharmingen), anti-pig CD4 (clone 74-12-4, isotype IgG2b), anti-pig
CD8α (clone 76-2-11, isotype Ig2a) (all from the Washington State University MAb
Center, Pullman, WA). Secondary antibodies included goat anti-mouse IgG2aphycoerythrin (PE), goat anti-mouse IgG2a-FITC, and goat anti-mouse IgG2b-PE-Cy7 (all
from Southern Biotech, Birmingham, AL). Cross-IFN-γ expression responses were
assessed by stimulation of the PBMCs collected from SVV 001- or SD15-26-inoculated
animals with both SVA strains used in our study (SVV 001 or SD15-26). Staining protocols
and assay controls have been previously described (23). Flow cytometry data was acquired
with the Attune NxT flow cytometer (Thermo Fisher Scientific) and data analysis was
performed using FlowJo software (TreeStar, San Carlos, CA). Data was corrected for
background proliferation and/or IFN-γ expression by subtracting the frequency of cells that
responded under non-stimulated conditions. Results from day 0 were used as baseline
comparisons on T cell responses detected on day 14 pi. Percentage of responding cells was
expressed as the percentage of live T cells (CD3+ cells).
Statistical analysis
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Statistical analysis was performed by analysis of variance followed by T-Student's or
Sidak's comparisons test. Statistical analysis and data plotting were performed using the
GraphPAD Prism 6.0 software (GraphPAD Software Inc., La Jolla, CA).
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Table 1. Comparative genome analysis between SVA SVV 001 and SD15-26.

5’UTRa
L
VP4
VP2
VP3

SVA SD15-26
nt id aa id
%
%
94.6 95.8 98.7
98.6 100
94.2 98.6
92.6 95.8

VP1
2A
2B
2C
3A

91.8
81.5
93.5
93.4
91.5

SVV 001

97
87.5
98.4
98.8
90

Substitution(s)
R56K
T165I, N368S, Y426F, A428T
L452I, E491G, V493A, P494S, V497E, T502A, T511A, R516K, T575A,
V603I
Q735A, E736T, A766V, G770D, F834Y, A845T, V894I, I912V
I941V
D988N, V1003I
K1079T, S1148G, N1366S, T1378A
S1397N, S1415T, T1427A, E1429D, R1462K, A1469T, G1478E,
S1479P, V1480A
T1547A, I1589L, S1628A, E1649D, L1685M,
I1729V, N1839S, V1850S, A1856P, V1860M

3B
94.2 100
3C
93.3 97.6
3D
95.5 98.9
3’UTR
95.6 ORF1
93.9 97.8
Genome 93.8 id: identity.
a
2 nt insertion (TC) at position 553–554 in SVA SD15–26 5ʹUTR.
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Fig 1. Comparative pathogenicity of SVA SVV 001 and SD15-26 in finishing pigs. (A)
Clinical course and progression of vesicular disease observed in SVA SD15-26-inoculated
animals. All the animals inoculated with SD15–26 presented lesions starting on day 4 pi.
Lesions were observed on the snout, interdigital space, dewclaws, heel and/or coronary
band. The black arrows indicate the lesions. (B) Clinical course observed in SVA SVV
001-inoculated animals. Animals inoculated with the SVA strain SVV 001 did not present
any vesicular lesion and remained clinically normal throughout the experiment. (C) Lesion
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score. Daily average group lesion scores were calculated. One point was attributed to each
foot or/and snout presenting a vesicular lesion for a total of five points per animal per day.
SVA SD15-26 (blue) and SVV 001 (red).
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Fig 2. Histological sections of the skin of SVA SD15-26 and SVV 001-inoculated animals.
(A-B) Vesiculopustular dermatitis observed in histological sections of SVA SD15-26inoculated animals on day 3 pi. Histological examination of the snout skin revealed
extensive areas of the epidermis presenting erosions to ulcerations with multifocal to
coalescing vesicles, which contained homogenous eosinophilic fluid (edema), fibrin and
necrotic debris, neutrophils and eosinophilic material, cellular and karyorrhectic debris and
numerous mixed bacteria (A). The lesion on the coronary band was characterized by
vesiculopustular dermatitis with mild, multifocal infiltration of inflammatory cells
composed of lymphocytes and plasma cells around the blood vessels in the dermis (B). (CD) Normal histological morphology observed in SVA SVV 001-inoculated animals. The
histology of the snout (C) and coronary band (D) of the animals inoculated with SVA strain
SVV 001 were unremarkable. Haematoxylin and eosin stain.
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Fig 3. Viremia and virus shedding in animals inoculated with Senecavirus A strains SVV
001 and SD15-26. (A) Viremia levels in serum as determined by RT-qPCR. Viral loads are
expressed as log10 genome copy number per mL−1. Virus shedding in oral (B) and nasal
(C) secretions and in feces (D) were determined by RT-qPCR and expressed as log10
genome copy number per mL−1. The animals inoculated with SVA strain SD15-26 are
represented in blue and the animals inoculated with SVV 001 strain are in red. The lines
represent the average of each group. P values were determined by Student's t-test
(**P < 0.05).
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Fig 4. Viral load and tissue distribution of Senecavirus A (SVA) strains SVV 001 and
SD15-26 were assessed in non-lymphoid tissues during acute infection in pigs. Viral load
in different tissues collected on days 3, 7 and 14 post-infection. Levels of SVA RNA in
heart (A), lungs (B), kidney (C), liver (D), small intestine (E) and large intestine (F) were
determined by RT- qPCR and expressed as log10 genome copy number mL−1. The animals
inoculated with SVA strain SD15-26 are represented in blue and the animals inoculated
with SVV 001 strain are represented in red. Error bars represent the standard error of the
mean (SEM).
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Fig 5. Viral load and tissue distribution of Senecavirus A (SVA) strains SVV 001 and
SD15-26 were determined in lymphoid tissues during acute infection in pigs. Viral load in
different tissues collected on days 3, 7 and 14 post-infection. Thymus (A), spleen (B),
mediastinal lymph node (C), mesenteric lymph node (D) and tonsil (E) were collected on
days 3, 7 and 14 post-infection. Levels of SVA RNA were determined by RT- qPCR and
expressed as log10 genome copy number mL−1. The animals inoculated with SVA strain
SD15-26 are represented in blue and the animals inoculated with SVV 001 strain are in
red. Error bars represent the standard error of the mean (SEM).
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Fig 6. Virus neutralization (VN) assays demonstrating cross-neutralizing antibody
responses against Senecavirus A (SVA) strains SVV 001 (A) and SD15-26 (B). The serum
of animals inoculated with SVA strain SD15-26 are represented in blue and the animals
inoculated with SVV 001 strain are in red. Error bars represent the standard error of the
mean (SEM). (**P < 0.05; ***P < 0.01).
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Fig 7. Infection with SVA SVV 001 or SD15-26 elicits cross-reactive T-cells.
Cryopreserved PBMCs isolated from SVA SVV 001- or SD15-26-inoculated pigs were
thawed and allowed to rest for 6 h. Cells were then cultured in the presence of UVinactivated SVA SVV 001 (MOI = 1), SVA SD15-26 (MOI = 1), cRPMI, or ConA
(5 µg/mL) plus PHA (5 µg/mL). At 4 h post stimulation, brefeldin A was added to the
culture and cells were further stimulated for 12 h (16 h culture/stimulation). After
stimulation, αβ T cells were analyzed for virus-specific IFN-γ expression as measured by
ICS. Gating strategy: Following doublet- (A) and dead cell- (B) exclusion, lymphocytes(C; based on forward scatter [FSC] and side scatter [SSC] properties), and total live CD3+
T cells were selected (D) and IFN-γ production by T cells (E) and the its main subsets
evaluated (F and G). Each subsequent panel shows only the population of interest that was
selected from the gate in the previous plot, as indicated by arrows. Collective results of
flow cytometric analysis are shown for each population of cells evaluated from SVA SVV
001 (H) or SVA SD15-26 infected animals (I) in response to recall stimulation with either
SVA SVV 001 (left side) or SVA SD15-26 (right side) on days 0 and 14 days postinfection. Data represent group means ± SEM. No statistical differences were detected by
Sidak's multiple-comparison test.
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ABSTRACT
Senecavirus A (SVA), an oncolytic picornavirus used for cancer treatment in
humans, has recently emerged as a vesicular disease (VD)-causing agent in swine
worldwide. Notably, SVA-induced VD is indistinguishable from foot-and-mouth disease
(FMD) and other high-consequence VDs of pigs. Here we investigated the role of apoptosis
on infection and replication of SVA. Given the critical role of the nuclear factor-kappa B
(NF-κB) signaling pathway on modulation of cell death, we first assessed activation of NFκB during SVA infection. Results here show that while early during infection SVA induces
activation of NF-κB, as evidenced by nuclear translocation of NF-κB-p65 and NF-κBmediated transcription, late in infection a cleaved product corresponding to the C-terminus
of NF-κB-p65 is detected in infected cells, resulting in lower NF-κB transcriptional
activity. Additionally, we assessed the potential role of SVA 3C protease (3Cpro) in SVAinduced host-cell apoptosis and cleavage of NF-κB-p65. Transient expression of SVA
3Cpro was associated with cleavage of NF-κB-p65 and Poly (ADP-ribose) polymerase
(PARP), suggesting its involvement in virus-induced apoptosis. Most importantly, we
showed that while cleavage of NF-κB-p65 is secondary to caspase activation, the
proteolytic activity of SVA 3Cpro is essential for induction of apoptosis. Experiments using
the pan-caspase inhibitor Z-VAD-FMK confirmed the relevance of late apoptosis for SVA
infection, indicating that SVA induces apoptosis, presumably, as a mechanism to facilitate
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virus release and/or spread from infected cells. Together, these results suggest an important
role of apoptosis for SVA infection biology.
Key words: Senecavirus A, Seneca Valley virus, apoptosis, 3C protease, virus
egress.
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Introduction
Senecavirus A (SVA) is a non-enveloped single-stranded positive-sense RNA virus
of the genus Senecavirus, family Picornaviridae (16, 17). SVA was first detected as a cell
culture contaminant in 2002 in the United States (US) (3), and subsequently identified as a
novel picornavirus closely related to members of the genus Cardiovirus (16). The SVA
genome is approximately 7.2 kb in length containing a single open reading frame (ORF)
that encodes a 2181 aa polyprotein, which is cleaved into four structural proteins (VP1,
VP2, VP3, and VP4) and eight non-structural proteins (L, 2A, 2B, 2C, 3A, 3B, 3C, and
3D) (16). Processing of the polyprotein into mature viral proteins is catalyzed by the nonstructural protein 3Cpro, a virus-encoded cysteine protease that contains a conserved His,
Asp, Cys catalytic triad (16, 66). While the structural proteins of picornaviruses form the
virus capsid and are involved in receptor binding and cell entry, non-structural proteins are
mainly responsible for virus replication (80) and play important roles on virus-host
interactions contributing to innate immune evasion, virus virulence and pathogenesis (30,
31, 33–39, 45, 46, 61, 71–73, 75, 77, 78, 97–101).
Since its identification, SVA has been associated with sporadic cases of vesicular
disease in pigs in the US and Canada (5, 8, 21). However, after 2014, outbreaks of vesicular
disease associated to SVA have been reported in major swine producing countries around
the world (6, 7, 9, 11, 102). The lesions observed during these outbreaks include vesicles
on the snout, oral mucosa and feet, involving the coronary bands, interdigital space, due
claws, and/or sole (1, 2, 7–9, 21). This clinical presentation was also observed in
experimentally infected animals (22, 23, 25, 83). Importantly, SVA-induced disease is
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clinically indistinguishable from other high consequence vesicular diseases of swine,
including foot-and-mouth-disease (FMD), swine vesicular disease (SVD), vesicular
stomatitis (VS), and vesicular exanthema of swine (VES) (21, 103).
In addition to its relevance to animal health, SVA has been tested as an oncolytic
agent for cancer treatment in humans (12, 13, 17, 104, 105). Given the promising results
in animal models, SVA was tested in phase I clinical trials, becoming the first oncolytic
picornavirus to be tested in humans (15, 105). The main limitations to the broad use of
SVA as an oncolytic agent in humans, however, are the development of neutralizing
antibodies that result in rapid viral clearance from treated patients and the fact that the
molecular basis of SVA's oncolytic activity remain unknown (14). A better understanding
of the molecular SVA-host interactions and of the mechanism(s) underlying virus
replication in susceptible cells may allow the development of improved SVA-based
therapeutics for cancer treatment.
Picornaviruses modulate many host cellular pathways, including the host
translation machinery, innate immune responses and cell survival or apoptosis. Foot-andMouth disease virus (FMDV), for example has been shown to inhibit nuclear factor kappa
B- (NF-κB) (30) and interferon beta (IFN-β) signaling (37). Enteroviruses, on the other
hand, were shown to take advantage of the host secretory autophagy pathway to enhance
their transmissibility (106) and cardioviruses were shown to inhibit nucleocytoplasmic
trafficking of host cell proteins (98). Another important cellular process that is targeted by
several picornaviruses is programmed cell death, or apoptosis. Poliovirus has been shown
to modulate apoptosis and is known to inhibit or induce host cell death during different
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phases of the infection (63, 64), while Coxsackievirus B3 (57), and Hepatitis A virus (59)
are known to induce apoptosis. Recently, apoptosis was observed in lesions caused by
FMDV in the tongue of experimentally infected pigs (62). These observations highlight
the importance of modulation of host cell apoptosis for the infection biology of
picornaviruses.
While apoptosis usually functions as a host defense mechanism that ensures killing
of infected cells (48, 107), several viruses, including picornaviruses, have been shown to
induce apoptosis to enable efficient virus transmission while avoiding overt inflammatory
responses and activation of the immune system (108). Activation of apoptosis occurs
mainly by two distinct pathways, the intrinsic and extrinsic pathways, which utilize
executioner caspases (Casp–3, –6, and –7) to induce cell death (48, 49). Caspases are a
family of serine proteases that mediate many features of apoptosis (107). These enzymes
are maintained in the cell cytoplasm as inactive proenzymes comprising two subunits (large
and small) and a variable amino terminal prodomain. Activation of the caspases requires
loss of the prodomain through catalytic cleavage of a C-terminal aspartate residue and
dimerization of the large and small subunits to form the active protease (107, 109).
Apoptotic responses are usually initiated by activation of Casp-8 or Casp-9 (via tumor
necrosis factor receptor or Fas, respectively), whose activity results in downstream
activation of the effector Casp–3, –6, and –7 (107, 109). These effector enzymes cause
cellular disassembly through cleavage of cell death substrates, including lamin, poly(ADPribose) polymerase (PARP) or the caspase-activated DNase/DNA fragmentation factor
(CAD/DFF) complex (110–112). Additional substrates of the effector caspases include
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pro-survival transcription factors, such as NF-κB (113, 114). Collectively, the action of the
caspases results in fragmentation of cellular DNA and cell death (107, 111, 112).
NF-κB is a ubiquitous transcription factor that modulates not only cell death but
also innate immunity and inflammatory responses. This pathway seems to play critical
roles in the picornaviral life cycle (30, 35, 45, 46, 71, 73, 75, 115, 116). Activation of the
NF-κB signaling pathway by viruses is mediated by pattern recognition receptors (PRRs)
which detect pathogen associated molecular patterns (PAMPs; including double-stranded
RNA [dsRNA] and/or viral proteins) and initiate the signaling cascade that leads to host
gene transcription (42, 43). In unstimulated cells, the NF-κB transcription factors (NF-κBp50, -p52, -p65, RelB, or c-Rel) form homo- or heterodimers (41), that are sequestered by
the NF-κB inhibitor alpha (NFκBIA/IκBα) in the cell cytoplasm (44). Once the pathway is
activated, IκBα is phosphorylated by upstream IκB kinases (IKKα, IKKβ), triggering its
proteasomal degradation and leading to translocation of NF-κB subunits to the nucleus,
where they undergo additional post-translational modifications and modulate transcription
of pro-inflammatory-, innate immunity-, and/or apoptosis-related genes (41). In this
context, NF-κB seems to play an essential role in protecting host cells from picornavirusinduced apoptosis (47).
In the present study, we investigated the host apoptotic responses during SVA
infection and dissected the interplay between the virus, host cell apoptosis and NF-κB
signaling. Results here show that SVA induces apoptosis late in infection, which plays a
critical role on the virus infection cycle, likely facilitating virus release from infected cells.
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Materials and Methods
Cells and Virus
Primary swine turbinate (STu) and NCI-H1299 non-small human lung carcinoma
cell lines (ATCC® CRL-5803) were cultured at 37°C with 5% CO2 in minimum essential
medium (MEM, Corning®) or RPMI 1640 medium (Corning®) supplemented with 20 or
10% fetal bovine serum (FBS; Seradigm), respectively. Cell culture media was
supplemented with 2 mM L-glutamine (Corning®), penicillin (100 IU/mL; Corning®),
streptomycin (100 µg/mL; Corning®), and gentamicin (50 µg/ml; Corning®). Senecavirus
A strain SD15-26 was isolated from a vesicular lesion from a finishing pig and has been
previously characterized (22). Low passage (passage 4) SVA stocks were prepared and
titrated in H1299 cells, and used in all experiments involving SVA infection described
here.
Plasmids
Luciferase reporter plasmids (pNF-κB-luciferase reporter, and pRL-TK control
plasmids) are commercially available (Promega). The coding sequence of SVA 3Cpro was
fused with Flag-tag (N-terminus fusion), chemically synthesized (GenScript), and cloned
into the pcDNA3.1 expression plasmid (pcDNA-Flag-3C). Additionally, SVA 3Cpro was
amplified from SVA strain SD15-26 by RT-PCR and cloned into the eukaryotic expression
plasmid pET28a as a His-tag fusion protein (pET28-SVA-3C). SVA strain SD15-26 VP1
expressing plasmid (pcDNA-HA-VP1) was kindly provided by Dr. Steve Lawson
(Department of Veterinary and Biomedical Sciences, South Dakota State University).

50
Control plasmid pCMV-Flag-BAP is commercially available (Sigma). The plasmid
pCMV-HA-NF-κB-p65 was constructed by standard cloning techniques. Briefly, porcine
NF-κB-p65 coding sequence (GenBank NM_001114281) was PCR amplified from cDNA
prepared from swine testicle (ST) cells and cloned in fusion with the HA epitope tag into
the pCMV-HA-N expression vector (Clontech). Sequence identity of the expression
plasmids generated here were confirmed by DNA sequencing.
Antibodies and Reagents
Antibodies against β-actin (clone C4), NF-κB-p65 (clone C-20; C-terminus), NFκB-p65 (clone F-6), and IκBα (clone H4) were purchased from Santa Cruz Biotechnology.
Antibodies against NF-κB-p65 (clone C22B4; N-terminus), IKKα (clone3G12), IKKβ
(D30C6), cleaved caspase-3 (Asp175, clone 5A1E), and PARP (clone 46D11) were
obtained from Cell Signaling. SVA VP1 and SVA VP2 mouse monoclonals and SVA
whole virus antibodies were kindly provided by Dr. Steve Lawson (SDSU). Anti-Flag or
anti-HA mouse monoclonal antibodies are commercially available (GenScript and Thermo
Scientific, respectively). Anti-rabbit and/or anti-mouse secondary antibodies conjugated
with Alexa Fluor® 594 and Alexa Fluor 488® were purchased from Life Technologies.
IRDye 800CW-labeled anti mouse IgG and IRDye 680-labeledRD anti rabbit IgG
secondary antibodies were purchased from Li-Cor Biosciences. Recombinant TNF-α was
obtained from InvivoGen. Staurosporine was purchased from Cell Signaling and Z-VADFMK was obtained from Santa Cruz Biotechnology.
SVA 3Cpro-Specific Rabbit Antibody Production
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SVA 3Cpro was expressed using a prokaryotic expression system. SVA 3Cpro coding
sequence (GenBank KX778101) was PCR amplified from cDNA of SVA SD15-26 and
cloned into the bacterial expression plasmid pET-28a (EMD Millipore/Novagen). The
recombinant protein was expressed in Escherichia coli strain BL-21 cells as a 6×His-tag
fusion protein and purified using nickel-charged agarose resin (Qiagen) according to the
manufacturer's instructions. Purified recombinant protein was used for polyclonal antibody
production in rabbits.
One adult 12-week old rabbit was kept in an individual cage with food and water
ad libitum throughout the study. The animal was immunized with 660 ng of SVA 3Cpro
emulsified in water-in-oil (W/O) adjuvant (1:1; 1 mL:1 mL; Montanide™ ISA 50 V2,
Seppic). The antigen was administered by three 0.5 mL subcutaneous injections and one
0.5 mL intramuscular injection. Two weeks post-primary immunization the animal
received a booster immunization as above. Two weeks after the booster immunization the
rabbit was euthanized and exsanguinated, and polyclonal serum containing SVA 3Cprospecific antibodies was isolated by centrifugation (at 2,000 × g for 15 min at 4°C). All
animal procedures and protocols for antibody production were reviewed and approved by
the South Dakota State University Institutional Animal Care and Use Committee (IACUC)
under approval number 15-095A.
Terminal Deoxynucleotidyltransferase-Mediated dUTP-Biotin Nick-End Labeling
(TUNEL)
Primary STu cells were cultured on glass cover slips and infected with SVA (MOI
= 5) or mock-infected and then fixed at 12 h p.i. with 3.7% formaldehyde in PBS (pH 7.2)
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for 20 min. Positive control cells were treated with 0.1 µM staurosporine for 4 h and then
fixed as above. Additionally, formaline-fixed paraffin-embedded (FFPE) tissue sections
from a previous SVA pathogenesis experiment conducted in our laboratory (25) were
subjected to TUNEL. Cell cultures or tissue samples were permeabilized and stained with
an in situ cell death detection kit (TUNEL, Abcam) according to the manufacturer's
instructions.
Histopathology
Formalin-fixed paraffin-embedded tissue sections (skin) from a previous SVA
animal experiment were processed following standard histological procedures and stained
with hematoxylin and eosin for histological examination. All animal procedures and
protocols were reviewed and approved by the SDSU IACUC under approval number 16002A.
In situ Hybridization
Formalin-fixed paraffin-embedded tissue sections (skin) were used to perform in
situ hybridization (RNAScope®). ISH probe utilized was specific for the viral genome
SVV (301-1345 region of VP1 gene, GenBank: EU271758.1, Advanced Cell Diagnostics,
Inc.). The ISH was performed as previous described (117).
Flow Cytometry
Activation of caspase 3 and 7 (Casp-3/-7) was assessed by flow cytometry during
SVA infection. Semi-confluent STu or H1299 cells were cultured in 12-well plates and
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infected with SVA (MOI = 5). At 2, 4, 5, 6, 7, 8, and 10 h p.i. the supernatant was removed
and the cells trypsinized to dissociate the monolayer. Mock-infected cells and mockinfected cells treated with 0.3 µM staurosporine were used as negative and positive
controls, respectively. After trypsinization, cells and supernatant were mixed and
centrifuged at 1,500 × g for 5 min at 4°C. Activation of Casp-3/-7 was assessed using the
CellEvent™ Caspase-3/7 Green Flow Cytometry Assay kit (Thermo Fisher Scientific)
according to manufacturer's protocol. The flow cytometry data were acquired with an
Attune NxT flow cytometer (Thermo Fisher Scientific) and analyzed using FlowJo
software (TreeStar).
To investigate activation of Casp-3/-7 in the context of NF-κB-p65 expression and
SVA infection, STu cells were transfected with 1 µg of pCMV-HA-NF-κB-p65 or empty
pCMV-HA plasmids (control) using Lipofectamine 3000 (Life Technologies) and
subsequently infected with SVA (MOI = 5). Cells were collected at 4, 7, 8, and 10 h p.i.
and processed for flow cytometry assessment of Casp-3/-7 activation as described above.
Growth Curve
SVA growth curves were performed in STu and H1299 cells. Cells were cultured
in 12-well plates, inoculated with SVA (MOI = 5) and harvested at 2, 4, 8, 12, and 24 h p.i.
Virus titers were determined on each time by limiting dilutions in H1299 cells. At 48 h p.i.
cells were fixed (3.7% formaldehyde), permeabilized (0.2% Triton-X), and stained with an
anti-SVA whole virus rabbit polyclonal antibody. Viral titers were determined by the
Spearman and Karber's method (118) and expressed as tissue culture infectious dose 50
(TCID50) per milliliter.
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The effect of NF-κB pathway activation during SVA replication was assessed by
overexpression of NF-κB-p65 in STu cells. For this, semi-confluent STu cells were plated
in 12-well plates and transfected with 1 µg of pCMV-HA-NF-κB-p65 or empty pCMVHA (control) per well using Lipofectamine 3000 (Life Technologies) as recommended by
the manufacturer. At 24 h post-transfection, cells were infected with SVA (MOI = 0.1).
After 1 h adsorption, the inoculum was removed, and fresh media was added. The cells
were harvested at 2, 4, 8, 12, and 24 h p.i. and virus titers determined as described above.
To assess the role of apoptosis on SVA infection cycle, multiple-step growth curves
were performed in STu or H1299 cells. Cells were plated in 12-well plates and infected
with SVA (MOI = 0.1). After 1 h adsorption, fresh media containing 30 µg/mL of Z-VADFMK, a pan-caspase inhibitor was added to the cells. Plain media was added to untreated
control wells. Cells and supernatant were collected separately at 2, 4, 8, 12, and 24 h p.i.
and subjected to virus titration. Additionally, the effect of apoptosis on SVA infection was
assessed in STu cells infected with a high MOI. For this, cells were infected with SVA at
an MOI = 5 and cells and supernatant collected separately at 8 h p.i. and subjected to virus
titrations.
RNA Extraction and Quantitative Reverse-Transcription-PCR (RT-qPCR)
To determine transcription levels of NF-κB target genes during SVA infection we
performed RT-qPCR. STu cells cultured in 6-well plates were infected with SVA (MOI =
5), collected at 2, 4, 8, and 12 h p.i., and cellular RNA extracted using TRIzol reagent
(Invitrogen) according to manufacturer's protocol. RNA samples were treated with DNase
(Ambion) and further cleaned using the RNeasy® Mini kit (QIAGEN). Mock infected cells
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were used as a negative control. Transcription levels of TNF-α, Caspase 8, FADD, BAX,
BAK, BCL-2, XIAP, CXCL8, PTGS2, IRF1, and NF-κBIA genes were determined using
RT-qPCR and TaqMan gene expression assays (Thermo Scientific). The housekeeping
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading control.
RT-qPCR reactions were performed using the RNA-to-Ct™ 1 Step-kit and TaqMan assays
for each target gene. The amplification/detection reactions were performed in a 7500 Real
Time PCR System (Applied Biosystems). Transcription of target gene was normalized to
that of GAPDH and genome copy numbers were determined using the relative quantitation
method. Data were analyzed and expressed as fold changes normalized to levels of RNA
detected in mock infected cells.
Indirect Immunofluorescence (IFA)
Expression and activation of NF-κB-p65 was assessed during early stages of SVA
infection by IFA. STu cells cultured in 24-wells plates were infected with SVA (MOI = 5).
At 0, 2, and 4 h p.i. cells were fixed using 3.7% formaldehyde in PBS (pH 7.2) for 20 min.
The cells were washed three times with PBS and permeabilized with 0.2% Triton X-100 in
PBS for 10 min at room temperature (RT). Plates were incubated for 1 h at RT with an
antibody specific for the C-terminus-NF-κB-p65 (1:250 in PBS/1% BSA) and for SVA
(1:250 in PBS/1% BSA). After primary antibody incubation, cells were washed as above
and incubated for 1 h at RT with appropriate secondary antibodies conjugated with Alexa
Fluor 594 and/or 488 (1:250 in PBS/1% BSA). Cells were washed three times with PBS
and nuclear stain was performed with DAPI (Thermo Scientific). Cells were visualized
using a fluorescence microscope (Olympus CKX53, 40× magnification).
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Expression and activation of NF-κB-p65 was also assessed during late stages of
SVA infection by IFA. STu cells cultured in 24-well plates were infected with SVA (MOI
= 1). At 7 and 8 h p.i. cells were fixed, and IFA was performed as described above.
The effect of SVA 3Cpro on expression of NF-κB-p65 was assessed by IFA. H1299
cells were transfected with pcDNA-Flag-3C (100 µg) expression plasmid and subjected to
IFA staining. C-terminus-NF-κB-p65 (1:250 in PBS/1% BSA) and Flag-Tag-specific
antibodies (1:250 in PBS/1% BSA) were used as primary antibodies. All IFA steps were
performed as described above.
Western Blots
The effect of SVA on apoptosis and NF-κB signaling pathway was investigated by
western blots. Semi-confluent monolayers of STu cells cultured in 6-well plates were
infected with SVA (MOI = 10) and harvested at 0.5, 1, 2, 3, 4, 8, and 12 h p.i. Mockinfected cells were used as negative controls. This experiment was also performed in
H1299 cells, with samples collected at 4, 8, 12, and 24 h p.i. Mock-infected cells
unstimulated or stimulated with 100 ng/mL of TNF-α were used as negative and positive
controls, respectively. Cells were lysed with M-PER mammalian extraction reagent
(Thermo Scientific) containing protease inhibitors (RPI). One hundred microgram whole
cell protein extracts were resolved by SDS-PAGE in 10% acrylamide gels and transferred
to nitrocellulose membranes. Blots were incubated with 5% non-fat dry milk in PBS
overnight at 4°C and then probed with the antibodies indicated in the Figures, followed by
incubation with appropriate Dye-light fluorescent conjugate secondary antibodies. The
membranes were scanned with the Odyssey infrared imaging system (Li-Cor).
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Densitometric analysis was performed using ImageJ® with expression levels of selected
target proteins being normalized to those of the housekeeping gene β-actin.
The effect of SVA 3Cpro on apoptotic pathways was assessed under transient
expression experiments. H1299 cells cultured in 6-wells plates were transfected with 2 µg
of pcDNA-Flag-3C and harvested at 18 h post-transfection. Positive control cells were
stimulated with TNF-α (100 ng/mL) for 1 h. In the experiments with catalytic dead mutants
of SVA 3Cpro, H1299 cells were transfected with 2 µg of pcDNA-Flag-3C, pcDNA-Flag3C(H47D), or pcDNA-Flag-3C(C159R) and harvested 18 h post-transfection. Protein
extracts and western blots were performed as described above.
To assess the expression of SVA 3Cpro during viral replication and its relationship
with the cleavage of NF-κB-p65 and apoptosis, STu cells were infected with SVA (MOI =
10) and collected the total protein extract at 2, 4, 5, 6, 7, 8, and 12 h p.i. Western blot was
performed as above, and the blots were probed with antibodies indicated in the Figures.
To determine the cleavage site of NF-κB-p65, semi-confluent H1299 cells were
cultured in 6-well plates and co-transfected with an empty plasmid (negative control) or
pcDNA-Flag-3C (2 µg/well) and either pCMV-HA-NF-κB-p65, pCMV-HA-NF-κBp65(478R/479D), pCMV-HA-NF-κB-p65(482R/483D), pCMV-HA-NF-κB-p65(478R483D),

pCMV-HA-NF-κB-p65(444L-450R),

pCMV-HA-NF-κB-p65(464V-467E),

pCMV-HA-NF-κB-p65(444L-450R 478R-483D), or pCMV-HA-NF-κB-p65(464V-467E
478R-483D) (1 µg of each). Cells were harvested at 18 h post-transfection and protein
extracts and western blots performed as described above. Antibodies used are indicated in
Figures 15B–D.
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To investigate if caspases or SVA 3Cpro were responsible for NF-κB-p65 cleavage,
semi-confluent H1299 cells were cultured in 6-well plates and co-transfected with an
empty plasmid (negative control) or pcDNA-Flag-3C (1 µg/well) and pCMV-HA-NF-κBp65 (2 µg/well). At 3 h post-transfection, fresh media was added to negative controls and
fresh media containing or not 150 µg/mL of Z-VAD-FMK was added to the cells
transfected with pcDNA-Flag-3C and pCMV-HA-NF-κB-p65. Cells were harvested at 18
h post-transfection and protein extracts and western blots performed as described above.
Antibodies used are indicated in Figure 15E.
Luciferase Reporter Assays
The effect of SVA on NF-κB-mediated transcription was investigated by luciferase
reporter assays. To detect the ability of SVA to inhibit NF-κB activation, semi-confluent
H1299 cells cultured in 24-well plates were co-transfected with the NF-κB-luciferase
reporter plasmid (315 ng/well) and the control plasmid pRL-TK (35 ng/well) using
Lipofectamine 3000 (Life Technologies) and infected with SVA (MOI = 5). SVA-infected
cells were stimulated or not with TNF-α (100 ng/mL) at 2, 4, 8, or 12 h p.i. and incubated
for 12 h post-TNF-α stimulation. Mock-infected cells were also stimulated with TNF-α for
12 h. The dual-luciferase reporter system (Promega) was used to determine the luciferase
activity in each treatment condition following the manufacturer's instructions. Firefly
luciferase activity was normalized to renilla luciferase activity and fold-changes calculated
based on the levels of luciferase detected in mock-infected/non-stimulated cells.
The effect of SVA 3Cpro on NF-κB-mediated transcription was investigated by
luciferase assays. H1299 cells were co-transfected with pNF-κB-luciferase reporter

59
plasmid (315 ng/well), pRL-TK (35 ng), and either pcDNA-Flag-3C (550 ng/well), or
control plasmids pCMV-Flag-BAP (550 ng/well) or pcDNA-HA-VP1 (550 ng/well). At
14 h post-transfection cells were stimulated with TNF-α, harvested at 12 h post-TNF-αstimulation and the luciferase activity was determined as described above.
To assess whether the proteolytic activity of 3Cpro is required for its effect on NFκB-mediated transcription, H1299 cells were co-transfected with pNF-κB-luciferase
reporter plasmid (315 ng/well), pRL-TK (35 ng), and either pcDNA-Flag-3C (550
ng/well), pcDNA-Flag-3C(H47D) (550 ng/well), or pcDNA-Flag-3C(C159R) (550
ng/well) expression plasmids. At 14 h post-transfection, cells were stimulated with TNFα, harvested at 12 h post-TNF-α-stimulation and the luciferase activity was determined as
described above.
Site-Direct Mutagenesis
Mutations in the catalytic triad of SVA 3Cpro and in the porcine NF-κB-p65 were
introduced in the SVA 3Cpro- and NF-κB-p65-encoding plasmids using the Q5® SiteDirected Mutagenesis Kit (New England BioLabs® Inc.) according to the manufacturer's
instructions. Site directed mutagenesis primers containing nucleotide substitutions
targeting amino acids H47 and C159 leading to substitutions of H to D, or C to R on SVA
3Cpro were designed and used with the site-direct mutagenesis protocol to generate the
mutant plasmids pcDNA-Flag-3C(H47D) and pcDNA-Flag-3C(C159R). NF-κB-p65specific primers containing nucleotide substitutions targeting the putative SVA 3Cpro
cleavage sites individually (478QL and 482QG) or simultaneously 478QLLNQG were
designed and used with the site-direct mutagenesis protocol, resulting in plasmids pCMV-

60
HA-NF-κB-p65(478R/479D), pCMV-HA-NF-κB-p65(482R/483D), and pCMV-HA-NFκB-p65(478R-483D), respectively. Primers containing nucleotide substitutions targeting
putative caspase cleavage sites in NF-κB-p65 coding sequence (444LQFDTDED and
464VFTD) were designed and used with site directed mutagenesis kit, resulting in plasmids
pCMV-HA-NF-κB-p65(444L-450R) and pCMV-HA-NF-κB-p65(464V-467E). Double
caspase and SVA 3Cpro cleavage site-mutants were also generated, resulting in plasmids
pCMV-HA-NF-κB-p65(444L-450R 478R-483D) and pCMV-HA-NF-κB-p65(464V467E 478R-483D). The sequences of each NF-κB-p65 mutant are indicated in Figure 15E.
Correct nucleotide substitutions were confirmed by DNA sequencing.
Three-Dimensional Protein Structure Prediction
The SVA 3Cpro template-based protein structure modeling was performed using
RaptorX web server (119). The best template for SVA 3Cpro was the 2wv4A [Foot-andMouth disease virus 3C, p-value 1.48e-09 (120)]. SVA 3Cpro structure prediction was
designed using the PyMOL Molecular Graphics System, version 2.0 Schrödinger, LLC.
Plaque Assay
Confluent primary STu cells cultured in 6-well plates were infected with serial 10fold dilutions of SVA (titer 107.88). After 1 h adsorption, the inoculum was removed and
fresh 1%-agarose media containing or not 50 µg/mL of Z-VAD-FMK was used to overlay
the cells. The agarose overlay was removed and cells were fixed at 24 h p.i. with 3.7%
formaldehyde in PBS (pH 7.2) for 20 min. The cells were stained with 1% Crystal Violet
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solution for 20 min and washed four times with PBS. The area in mm2 of each viral plaque
was calculated using ImageJ®.
Statistical Analysis
The average of three independent experiments is presented where appropriate. Error
bars represent standard error of the mean (±SEM). Statistical significance of the data was
assessed using the Students' t-test, Mann-Whitney U-test or Sidak's multiple comparisons
test. The level of statistical significance was defined as p < 0.05.
Results
SVA Infection Induces Apoptosis in vitro and in vivo
Replication of SVA in primary STu cells induces cytopathic effect (CPE)
characterized by cell rounding and plasma membrane blebbing (Figure 8A). Therefore,
induction of apoptosis was investigated during SVA infection. Initially, TUNEL was
performed in SVA-infected cells to detect exposed 3′-OH ends of DNA fragments, which
are generated in response to apoptotic signals. As shown in Figure 8B, apoptotic nuclei
were detected in SVA-infected cells and cells treated with staurosporine (a potent inducer
of apoptosis) (arrows), suggesting induction of apoptosis during SVA infection.
To assess whether apoptosis occurs during viral infection in the swine host in vivo,
paraffin-embedded skin sections collected from SVA-infected pigs on day 7 post-infection
(p.i.), were subjected to TUNEL. Skin sections were obtained from characteristic SVA
vesicular lesions (Figure 8C). Sequential skin sections were subjected to H&E staining,
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ISH to detect SVA RNA and TUNEL to detected apoptosis. As shown in Figure 8D, strong
brown staining indicating the presence of apoptotic cells was detected by TUNEL (Figure
8D, middle panels), in an area that presented histological changes caused by SVA
replication in the dermis and epidermis (Figure 8D, left panels), and that coincided with
the ISH staining for SVA RNA (Figure 8D, right panels).
Since Casp-3/-7 are the main executioners of apoptosis, and are responsible for the
proteolytic cleavage of many cellular proteins during cell death (107), we assessed their
activation during SVA infection by flow cytometry. SVA induced activation of Casp-3/-7
from 7 h p.i. onward in STu cells, with an increasing number of cells containing active
caspases detected until 10 h p.i. (Figures 9A, B). Notably, the frequency of live cells with
active Casp-3/-7 representing cells in early stages of apoptosis were ~4-fold higher at 8 h
p.i. (25.56%; p < 0.05) than those detected at 7 h p.i. (6.29%, when compared to mockinfected cells) (Figure 9B). Interestingly, at 10 h p.i., the percentage of active Casp-3/-7
detected in Sytox-green positive cells, indicating late stages of apoptosis, reached 46.23%
(p < 0.01 when compared to mock-infected cells). A significant increase in the frequency
of cells presenting active Casp-3/-7 was also detected at 8–10 h p.i. (7.6–14.2%, p < 0.01
when compared to mock-infected cells) in SVA-infected H1299 cells (Figure 9C). Similar
to the results in STu cells, the frequency of late-stage apoptotic cells (Casp-3/7 and Sytox
positive cells) was markedly increased at 10 h p.i. in H1299 cells. These results
demonstrate that Casp-3/-7 are activated between 7 and 10 h post-SVA infection, which
corresponds to the time in which the virus completes one round/cycle of replication (Figure
9D). Together these results demonstrate that SVA infection induces apoptosis late during
infection in vitro and in skin lesions in the natural swine host in vivo.
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SVA Infection Modulates Expression of Pro-Inflammatory and Apoptosis Related
Genes
NF-κB is one of the major players modulating host cell apoptosis and proinflammatory responses (52, 121). Thus, we assessed transcription of NF-κB-regulated
genes during SVA infection. For this, STu cells were mock-infected or infected with SVA
(MOI = 5) and total RNA was extracted during infection (2, 4, 8, and 12 h). As shown in
Figures 10A–F, all pro- (Casp-8, FADD, BAX, and BAK) or anti-apoptotic (BCL-2 and
XIAP) genes tested were down regulated at early time points post-SVA infection (2–4 h
p.i.) (p < 0.05 when compared to mock-infected cells). Additionally, the pro-inflammatory
NF-κB-regulated genes, including CXCL8, PTGS2, IRF1, NF-κBIA, and TNF-α were upregulated during SVA infection (4–12 or 8–12 h p.i.) (Figures 10G–K). These results
suggest modulation of NF-κB-regulated gene expression during SVA infection in primary
STu cells.
Effect of SVA Infection on the NF-κB Signaling Pathway
Given the transcriptional changes and modulation of apoptotic pathway observed
in SVA infected cells (Figures 9 and 10), we investigated activation of NF-κB signaling
during SVA infection. Since NF-κB-p65 is one of the key NF-κB subunits, that is directly
responsible for the transactivation of NF-κB target genes (78), expression and activation
of NF-κB-p65 were assessed in SVA infected cells using IFA. As shown in Figure 11, at
~2 h p.i. NF-κB-p65 translocated to the nucleus of cells, indicating activation of the NFκB pathway following SVA infection.
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Interestingly, at later times p.i. (7–8 h p.i.) on a low MOI experiment, many of the
SVA-infected cells presented a marked decrease in expression of NF-κB-p65 (Figure 12A),
suggesting potential degradation or cleavage of the C-terminus region of this transcription
factor. To assess whether the decreased levels of NF-κB-p65 observed in SVA-infected
cells at late times p.i. occurred due to degradation or cleavage of the C-terminus of the
molecule, expression of NF-κB-p65 was evaluated throughout the virus infection cycle
using western blots. As shown in Figure 12B, similar levels of N- and C-terminus NF-κBp65 were detected in SVA infected cells up to 4 h p.i., when compared to control mockinfected cells. At 8 h p.i., a marked decrease in the levels of NF-κB-p65 (~70% compared
to the average of mock cells) was observed in SVA-infected cells (p < 0.05; Figure 12B).
Notably, accumulation of a cleaved product of ~50 kDa, corresponding to N-terminus of
NF-κB-p65 was detected at 8–12 h p.i. (Figure 12B). Similar results were observed in the
human carcinoma cell line H1299 (Figure 12C).
NF-κB transcriptional activity was assessed during SVA infection using an NF-κBluciferase reporter assay. A significant decrease in TNF-α-induced NF-κB-mediated
luciferase activity was observed between 8 and 12 h post-SVA infection (Figure 12D).
Collectively, these results demonstrate a fine modulation of NF-κB pathway during SVA
infection. While early during infection the NF-κB pathway is activated, at later times p.i.,
SVA infection induces cleavage of NF-κB-p65, which results, in lower transcriptional
activity of this important modulator of host cell inflammation and survival.
Expression of SVA 3Cpro Is Associated With Apoptosis and Cleavage of NF-κBp65
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Next we sought to dissect the mechanisms underlying SVA-induced host-cell
apoptosis and its link with cleavage of NF-κB-p65. First, we assessed the potential role of
SVA non-structural protein 3Cpro, the main protease encoded by the virus (16), on apoptosis
and cleavage of NF-κB-p65 using western blots. Expression of IKKα, IKKβ, IκBα, and
NF-κB-p65 were investigated. Additionally, cleavage of PARP, a hallmark of host cell
apoptosis (122), was also assessed in 3Cpro expressing cells. While expression of 3Cpro did
not affect expression levels of the upstream NF-κB kinases (IKKα, IKKβ) (Figure 13A), a
marked decrease in the levels of IκB-α and NF-κB-p65 were observed in 3Cpro expressing
cells (Figure 13A). Accumulation of the cleaved 50 kDa-NF-κB product, observed in SVAinfected cells (Figures 12B, C), was also detected in 3Cpro expressing cells, when protein
extracts were probed with the antibody against N-terminus NF-κB-p65 (Figure 13A). IFA
experiments using an antibody specific for the C-terminus region of NF-κB-p65 confirmed
decreased levels of C-terminus NF-κB-p65 in 3Cpro expressing cells (Figure 13C). Similar
results were observed in primary STu cells (data not shown). Importantly, expression of
SVA 3Cpro also resulted in cleavage of PARP (Figure 13A), suggesting that the viral
protease induces apoptosis when expressed outside the context of SVA infection.
The effect of SVA 3Cpro expression on cleavage of NF-κB-p65 and activation of
apoptotic pathways in the context of SVA infection were investigated by western blots.
Expression of SVA 3Cpro was first detected using a SVA 3Cpro-specific rabbit polyclonal
antibody at 5 h p.i., with increasing levels of the protein being detected up to 12 h p.i.
(Figure 13B). Decreased levels of C-terminus NF-κB-p65 were observed after 7 h postSVA infection (0.88) (Figure 13B). In addition, accumulation of the cleaved 50 kDa-NFκB product was observed at 8 h p.i. (Figure 13B). Notably, a decrease in the levels of the
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full-length PARP was evident after 5 h p.i., with a cleaved product of the protein
accumulating in infected cells after 8 h p.i. (Figure 13B). Detection of cleaved Casp-3 at
8–12 h p.i. confirmed induction of apoptosis late during SVA infection (Figure 13B).
The effect of 3Cpro expression on the transcriptional activity of NF-κB was
investigated using a luciferase reporter assay. Expression of SVA 3Cpro in H1299 cells
completely suppressed TNF-α-induced NF-κB-luciferase activity (Figure 13D) as
evidenced by significantly decreased luciferase activity in SVA 3Cpro-expressing cells
(~2.2-fold, p < 0.05) when compared to cells expressing either VP1- or BAP-control
proteins (Figure 13D). These results indicate that expression of SVA 3Cpro results in
reduced NF-κB-mediated transcription following stimulation of cells with TNF-α.
Collectively, these findings suggest that expression of SVA 3Cpro could be associated with
cleavage of NF-κB-p65 and induction of apoptosis in SVA infected cells.
The Protease Activity of 3Cpro Is Required for Induction of Apoptosis and Cleavage
of NF-κB-p65
To assess whether the protease activity of SVA 3Cpro contributes to induction of
apoptosis and/or cleavage of NF-κB-p65, we constructed two plasmids encoding for
mutants of SVA 3Cpro. The picornavirus 3Cpro contains a conserved catalytic triad (His,
Asp, Cys) that is required for its protease activity (66, 67). To disrupt the catalytic triad
and, consequently, the proteolytic activity of SVA 3Cpro we introduced a mutation at His
47 (H47D) or Cys 159 (C159R) using site-directed mutagenesis (Figure 14A). The effect
of these mutations on apoptosis and cleavage of NF-κB-p65 were investigated in 3Cproexpressing cells. H1299 cells were transfected with plasmids encoding the wild type or

67
each of the 3Cpro mutants (H47D or C159R) and total protein extracts were subjected to
western blot analysis. Notably, while expression of the wild type SVA 3Cpro resulted in
activation of Casp-3 and cleavage of NF-κB-p65, expression of the 3Cpro catalytic dead
mutants H47D or C159R did not lead to Casp-3 activation nor NF-κB-p65 cleavage (Figure
14B).
The effect of SVA 3Cpro protease activity on NF-κB-mediated gene transcription
was investigated using luciferase reporter assays. Notably, while expression of the wild
type SVA 3Cpro markedly inhibited TNF-α-induced NF-κB-mediated luciferase activity (p
> 0.05), expression of the 3Cpro mutants (H47D and C159R) did not inhibit TNF-α-induced
NF-κB-mediated luciferase activity (Figure 14C). These results suggest that the protease
activity of SVA 3Cpro may be the trigger that leads to host cell apoptosis and potentially to
cleavage of NF-κB-p65 in host cells.
Assessing the Mechanism of NF-κB-p65 Cleavage
To dissect whether cleavage of NF-κB-p65 is directly mediated by SVA 3Cpro or
whether it is secondary to caspase activation following 3Cpro expression, we generated a
panel of plasmids encoding NF-κB-p65 proteins containing mutations on predicted
cleavage sites for Casp-3/-6 (123) and/or for the SVA 3Cpro (Figure 15A). Two cleavage
sites for 3Cpro (Q/L or Q/G, 478QL, and 482QG) (Figure 15A) and two cleavage sites for
caspases (444LQFDTDED and 464VFTD) were identified in the transactivation domain
(TAD) of NF-κB-p65 (Figure 15A). These predicted cleavage sites were mutated using site
directed mutagenesis and resultant plasmids used in transient expression experiments.
(Figure 15A). Cleavage of NF-κB-p65 was evaluated after transient co-expression of wild
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type- or mutant NF-κB-p65 proteins and the SVA 3Cpro by western blots. As shown in
Figure 15B, all NF-κB-p65 constructs with mutations on predicted cleavage sites for SVA
3Cpro were cleaved when co-expressed with the viral protease. Notably, when the NF-κBp65 containing mutations in the predicted cleavage sites for cellular caspases (444L-450R
and 464V-467E) were co-expressed with 3Cpro, NF-κB-p65 464-467E mutant was cleaved,
while no cleavage of NF-κB-p65 444L-450R mutant was observed (Figure 15C). This
phenotype was confirmed in double NF-κB-p65 mutants, containing 3Cpro- and Caspcleavage site mutations. As shown in Figure 15D, when the mutation 444L-450R in the
caspase cleavage site was introduced in NF-κB-p65 containing a mutation on the 3Cpro
cleavage site (478R-483D), NF-κB-p65 was not cleaved (Figure 15D). Additionally,
inhibition of caspases by incubation of cells with Z-VAD-FMK (a pan caspase inhibitor)
prevented cleavage of NF-κB-p65 in cells expressing 3Cpro (Figure 15E). Together, these
results show that NF-κB-p65 cleavage occurs at the caspase cleavage site
(444LQFDTDED), suggesting that cleavage of NF-κB-p65 is mediated by caspases and
not by the direct action of SVA 3Cpro.
Link Between NF-κB-p65 and Apoptosis During SVA Infection
Given our results demonstrating the association between cleavage of NF-κB-p65,
and host cell apoptosis late in SVA infection, we investigated the importance of this process
on virus replication. First, we assessed the effect of NF-κB-p65 on SVA-induced apoptosis
using a Casp-3/-7 flow cytometry-based assay in STu cells transiently expressing NF-κBp65. Notably, expression of NF-κB-p65 resulted in markedly low activation of Casp-3/-7
following SVA infection when compared to cells transfected with an empty control
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plasmid (Figure 16A). Indeed, when NF-κB-p65 was expressed, caspase activation levels
in SVA-infected- or staurosporine-treated cells were similar to those observed in mockinfected cells (Figure 16A). These results indicate that overexpression of NF-κB-p65
prevents SVA-induced apoptosis in STu cells.
Since expression of NF-κB-p65 led to reduced levels of apoptosis in SVA infected
cells, we next assessed its effect on SVA replication. Expression of NF-κB-p65 in both
STu or H1299 cells resulted in reduced viral yields as evidenced by significantly lower
viral titers in cells expressing NF-κB-p65, when compared to cells transfected with the
empty control plasmid (p < 0.05, STu; p < 0.01, H1299) (Figures 16B, C). Together these
results suggest that Casp-mediated cleavage of NF-κB-p65 (Figure 15) and induction of
host cell apoptosis late during SVA infection (Figure 9) might be critical for virus
replication and/or release from infected cells.
Late Induction of Apoptosis Seems Essential for SVA Infection Cycle
Given our results demonstrating that overexpression of NF-κB-65 prevents SVAinduced apoptosis and results in lower viral yields from infected cells, we investigate the
direct effect of apoptosis on SVA infection. For this, replication kinetics experiments were
performed in cells treated or not with Z-VAD-FMK to directly inhibit caspase-mediated
apoptosis (124). As shown in Figures 17A and B, viral yields were lower in both STu and
H1299 cells when apoptosis was inhibited (Z-VAD-FMK+).
Next, viral yields were evaluated in the supernatant or cell fraction of cell cultures
treated with Z-VAD-FMK following high MOI SVA infection. Cells were infected with
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SVA (MOI = 5) and treated or not with apoptosis inhibitor (Z-VAD-FMK). While no
differences in viral yields were detected in the cell fraction at 8 h p.i. (Figure 17C),
significantly lower viral titers were detected in the supernatant of cells treated with ZVAD-FMK when compared to control untreated cells. Additionally, the effect of apoptosis
on SVA spread was assessed by plaque assays. As shown in Figure 17D, inhibition of
apoptosis by Z-VAD-FMK decreased the ability of SVA to spread from cell-to-cell, as
evidenced by markedly smaller viral plaques in cells treated with the apoptosis inhibitor (p
< 0.001). Together these results suggest that induction of apoptosis late in SVA infection
may be important for SVA release and/or spread from infected cells.
Discussion
Programmed cell death or apoptosis is induced by infection with several
picornaviruses (47, 59, 62, 125–127). Here, we demonstrated the occurrence of apoptosis
at late times post-SVA infection and provided evidence that this process may contribute to
virus release from infected cells. Notably, early in SVA infection, the apoptotic pathway is
not activated, as evidenced by low Casp-3/-7 activity or lack of PARP cleavage in SVA
infected cells (Figures 9A, 13B). Suppression of apoptosis early in infection likely allows
the virus to complete the replication cycle before cell death/lysis (128). Inhibition of
apoptosis in early stages of infection has also been described for Coxsackievirus (129) and
Enterovirus 71 (130). Similar to our results with SVA, poliovirus, the prototype of the
Picornaviridae family (131), was shown to suppress host cell death at early stages of
infection and to trigger apoptosis at late times p.i. (63, 64, 132). Induction of apoptosis late
in infection is thought contribute to picornavirus release from infected cells (69). Results
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here showing reduced SVA titers in the supernatant of cells treated with apoptosis inhibitor
Z-VAD-FMK are aligned with this hypothesis.
Given that cleavage of NF-κB-p65 was detected in SVA infected cells, we
investigated the potential role of SVA viral protease 3Cpro on this function. The 3Cpro is the
only protease encoded by SVA and it plays a critical role during virus replication by
processing the polyprotein into mature proteins (16, 133). Additionally, 3Cpro is important
in virus-host interactions and functions as a key modulator of viral immune evasion (45,
46, 69, 71–73, 75). When SVA 3Cpro was transiently expressed in cell culture in vitro, a
cleaved fragment of NF-κB-p65 similar to the one observed in the SVA infected cells, was
detected. SVA 3Cpro also inhibited TNF-α-induced NF-κB-mediated luciferase expression,
suggesting that cleavage of NF-κB-p65 leads to a decreased trans-activating activity of this
transcription factor. This was also observed in the context of SVA infection, with lower
NF-κB-mediated luciferase activity detected at 8–12 h post-SVA infection. An important
observation to note is the fact that cleavage of NF-κB-p65 is not complete in SVA infected
cells. This is reflected in the luciferase activity (Figure 12D), which shows repression of
NF-κB transcriptional activity, but not complete inhibition of the transcription factor.
These observations would likely explain the detection of mRNA of NF-κB-target genes
late in SVA infection.
Additionally, transient expression of SVA 3Cpro led to cell membrane blebbing
(data not shown) and cleavage of PARP, a key marker of cell death, suggesting that this
viral protease is involved on host cell apoptosis (Figure 13A). This was also observed in
the context of SVA infection, in which expression of SVA 3Cpro correlated with decreased
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levels of PARP and cleavage of NF-κB-p65. The ability of 3Cpro to induce apoptosis seems
to be conserved in picornaviruses including Enterovirus 71 (55, 56), Poliovirus (76),
Coxsackievirus B3 (32), and Hepatitis A virus (61).
The picornaviral 3Cpro contains a His-Asp-Cys catalytic triad (66, 67). This site,
known as peptide-binding cleft, is located at the interface between two β-barrels (67),
which is characteristic of serine proteases (68). The predicted catalytic triad of SVA 3Cpro
consists of histidine 47 (H47), aspartate 83 (D83), and cysteine 159 (C159). To assess the
importance of the proteolytic function of SVA 3Cpro to its pro-apoptotic activity and
inhibitory effect on the NF-κB pathway, we generated two 3C mutants containing single
aa substitutions at H47 (H47D) and C159 (C159R) to disrupt the catalytic triad of the
protein. Notably, while expression of wild type 3Cpro resulted in activation of caspases and
cleavage of NF-κB-p65, mutations on the catalytic triad of 3Cpro (H47D and C159R)
abolished these phenotypes, indicating that the protease activity of SVA 3Cpro is essential
for its function on these pathways.
Cleavage of NF-κB-p65 has also been observed during infection with poliovirus
(45) and FMDV (30), and this phenotype was attributed to the expression of 3Cpro or Lpro
by these viruses, respectively. Initial results here, suggested that SVA 3Cpro could also be
potentially be involved with this function. However, since cellular caspases are also able
to cleave NF-κB-p65 (113, 114), we devised experiments to dissect the mechanism
underlying SVA-induced cleavage of this important transcription factor. For this, NF-κBp65-expressing plasmids containing single or double mutations in predicted cleavage sites
for the SVA 3Cpro and/or effector caspases were generated by site directed mutagenesis
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(Figure 15A). Notably, results from co-transfection and caspase inhibition experiments
suggest that cleavage of NF-κB-p65 occurs due to the activity of cellular caspases and not
due to the direct action of SVA 3Cpro (Figure 15E). Our results show that NF-κB-p65 is
cleaved at a Casp-3/-6 predicted cleavage site (444LQFDTDED) when host cell apoptotic
pathways are activated by expression of SVA 3Cpro (Figures 15B–D). Although, previous
studies with poliovirus suggest that cleavage of NF-κB-p65 is mediated by 3Cpro (45), our
findings using mutant NF-κB-p65 expressing plasmids provide evidence that, for SVA,
cleavage of this important pro-survival molecule is likely secondary to caspase activation.
Several studies demonstrated that caspase-mediated cleavage of NF-κB-p65
abrogates cell survival signaling, leading to host cell apoptosis (113, 114). Notably,
infection with Human Immunodeficiency virus (HIV) and African Swine fever virus
(ASFV) were shown to induce caspase-mediated cleavage of NF-κB-p65 resulting in
enhanced viral replication (134), or induction of apoptosis after completion of the virus
replication cycle (135), respectively. Here we demonstrated the relevance of caspasemediated cleavage of NF-κB-p65 for SVA infection. Overexpression of NF-κB-p65
suppressed SVA-induced apoptosis (Figure 16A), and resulted in significantly lower viral
yields from infected cells (Figures 16B, C). These results suggest that when high levels of
NF-κB-p65 are present, caspase-mediated cleavage of NF-κB-p65 may be saturated
resulting in decreased levels of viral-induced apoptosis. These findings highlight the
relevance of late apoptosis for SVA infection. This was confirmed with experiments in
which apoptosis was inhibited throughout the virus infection cycle using the pan-caspase
inhibitor Z-VAD-FMK. Results from these experiments demonstrated lower viral yields
from cells in which apoptosis was suppressed. These findings suggest that SVA induces
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apoptosis late in infection, presumably as a mechanism to facilitate virus release and/or
spread from infected cells (Figure 17C). Indeed, the primary mode of spreading of nonenveloped viruses is cell lysis (136), and apoptosis could allow viruses to use cell remnants
for viral transmission, while avoiding the host immune response (108).
In summary, results here show that SVA modulates important host cell pathways,
including NF-κB and apoptosis, throughout the infection cycle. The proteolytic activity of
SVA 3Cpro is essential to induction of apoptosis, however the precise function of the viral
protease to this process remains unknown. Our data demonstrate that induction of apoptosis
late in infection is a critical process for SVA infection in vitro. Results showing induction
of apoptosis in vivo suggest that this event may also have direct implications on SVA
infection and pathogenesis in the natural swine host.
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Fig 8. SVA induces apoptosis in vitro and in vivo (A) Cytopathic effect (CPE) caused by
SVA in cell culture. Mock-infected (left panel) or SVA-infected (MOI = 5, right panel)
primary swine turbinate (STu) cells. 40× magnification. (B) TUNEL staining of mockinfected- (left panel), staurosporine-treated- (middle panel) and SVA infected (right panel,
MOI = 5) STu cells. 40× magnification. The black arrows indicate apoptotic cells. (C, D)
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Apoptosis occurs during SVA infection in the swine host in vivo. Sequential paraffinembedded skin lesions collected from SVA-infected pigs on day 7 post-infection (C) were
subjected to hematoxylin and eosin staining (D, left panels), TUNEL (D, middle panels),
and in situ hybridization for detection of SVA RNA (RNAScope®) (D, right panels). 4×
(top panels) and 40× (bottom panels) magnifications. Areas highlighted in the top panels
are represented in the bottom higher magnification images.
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Fig 9. Activation of caspases 3/7 (Casp-3/-7) during SVA infection. (A) Gating strategy
used to determine percent of cells with active Caspase-3/7 and stained with Sytox-green
during SVA infection. Caspase activation was determined using the CellEventTM
Caspase-3/7 Green Flow Cytometry Assay kit. (B, C) Caspase-3/7 activation in STu or
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H1299-infected cells (MOI = 5) negative (left panel) or positively (right panel) stained with
Sytox-green, representing live cells (early apoptotic cells), or dead cells (late apoptotic
cells). The flow cytometry data were acquired with an Attune NxT flow cytometer and
analyzed using FlowJo software. The results represent the average of three independent
experiments in STu (B) or H1299 (C) cells. Error bars represent SEM calculated based on
the results of the independent experiments; **p < 0.05 and ***p < 0.01, compared to mockinfected cells. (D) Single-step growth curves of SVA (MOI = 5) in STu or H1299 cells.
Cells were collected at indicated time points and virus titers expressed as log10 tissue
culture infections dose 50 (TCID50) per milliliter. The results represent the average of three
independent experiments. Error bars represent SEM.
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Fig 10. Expression levels of select NF-κB target genes during SVA infection. Expression
of pro-apoptotic (Caspase 8, FADD, BAX, and BAK), anti-apoptotic (BCL-2 and XIAP)
and pro-inflammatory (CXCL8, PTGS2, IRF1, NFκBIA, and TNF-α) genes were assessed
by RT-qPCR at different time points post-SVA infection in primary swine turbinate (STu)
cells (2, 4, 8, and 12 h; MOI = 5). Expression levels of Caspase 8 (A), FADD (B), BAX
(C), BAK(D), BCL-2 (E), XIAP (F), CXCL8 (G), PTGS2 (H), IRF1 (I), NFκBIA (J), and
TNF-α (K) were normalized to that of Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH). Mock-infected cells were used as negative control. The results were expressed
as relative fold changes in mRNA levels compared to mock-infected cells. The results
represent the average of three biological replicates. Error bars represent SEM, **p < 0.05
and ***p < 0.01, compared to mock-infected cells.
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Fig 11. Effect of SVA on expression of NF-κB-p65 in STu cells in early stages of infection.
Primary swine turbinate (STu) cells were infected with SVA (MOI = 5) and stained with a
SVA VP2 monoclonal antibody (middle panel; green—Alexa fluor 488) and a rabbit
polyclonal antibody specific for C-terminus of NF-κB-p65 (left panel; red—Alexa fluor
594). The cell nuclei were stained with DAPI (right panel; blue). 40× magnification.

81

Fig 12. NF-κB-p65 is cleaved during SVA infection. (A) Immunofluorescence of primary
swine turbinate (STu) cells infected with SVA (MOI = 1) and stained with a monoclonal
antibody specific for SVA VP2 (middle panel; green—Alexa fluor 488) and a rabbit
polyclonal antibody specific for C-terminus of NF-κB-p65 (left panel; red—Alexa fluor
594). The cell nuclei were stained with DAPI (right panel; blue). 40× magnification. The
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white arrows indicate the cells infected with SVA. (B, C) Western blot analysis of primary
STu or H1299 showing cleavage of NF-κB-p65 during SVA infection. Total protein
extracts were analyzed by western blot using antibodies specific to N-terminus NF-κBp65, C-terminus NF-κB-p65, SVA VP1, or β-actin. Densitometric analysis was performed
to quantify the levels of C-terminus NF-κB-p65. The densitometry of C-terminus NF-κBp65 bands were normalized to the β-actin control and expressed as relative densitometry to
mock infected control cell (numbers on top of NF-κB-p65 blot; *p < 0.05; compared to
mock-infected cells). The results are representative of four independent experiments. (D)
Luciferase reporter assays in H1299 cells during SVA infection. Cells were infected and
stimulated with TNF-α at the indicated time points. Firefly luciferase activity was
determined at 12 h post-TNF-α stimulation and normalized to the renilla luciferase
activities. The results were expressed as relative fold changes in luciferase activity (**p <
0.05 and ***p < 0.01, compared to mock-infected TNF-α-stimulated cells). Error bars
represent SEM calculated based on the results of the three independent experiments.
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Fig 13. Expression of SVA 3Cpro is associated with apoptosis and cleavage of NF-κB-p65.
(A) Western blot analysis of H1299 cells transiently expressing SVA 3Cpro demonstrating
cleavage of NF-κB-p65 and PARP. Non-transfected cells were stimulated or not with TNFα for 1 h, and used as negative and positive controls, respectively. Total protein extracts
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were analyzed by western blots using antibodies indicated on the left. The results are
representative of three independent experiments. (B) Western blot analysis of STu cells
demonstrating cleavage of NF-κB-p65 and PARP during SVA infection. Total protein
extracts were analyzed using antibodies indicated on the left. Densitometric analysis was
performed to quantify the levels of C-terminus NF-κB-p65. The densitometry of Cterminus NF-κB-p65 bands were normalized to the β-actin control and expressed as relative
densitometry to mock infected control cells. (C) Immunofluorescence staining showing
decreased levels of NF-κB-p65 in in SVA 3Cpro expressing H1299 cells. Flag-tag antibody
(red—Alexa fluor 594) and rabbit polyclonal antibodies specific for C-terminus NF-κBp65 (green—Alexa fluor 488). The cell nuclei were stained with DAPI (blue). 40×
magnification. The white arrows indicate the cells expressing SVA 3Cpro (red). (D)
Luciferase reporter assays in H1299 cells expressing SVA 3Cpro. At 14 h post-transfection
of luciferase and 3Cpro expressing plasmids, cells were stimulated with TNF-α for 12 h
(TNFα+) or left unstimulated (TNF α-). Luciferase activity was determined, and firefly
luciferase activity normalized to renilla luciferase activity. The results were expressed as
relative fold changes in luciferase activity (**p < 0.05; ***p < 0.01; compared Flag-BAP
and HA-VP1 expressing cells). Data shown represent the average of five independent
experiments. Error bars represent SEM calculated based on the results of the independent
experiments. Western blot showing expression of BAP, SVA 3Cpro, and VP1 in samples
examined by luciferase assays (bottom panel).
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Fig 14. The protease activity of 3Cpro is required for induction of apoptosis. (A) Threedimensional protein structure prediction. The wild type SVA 3Cpro and the 3Cpro mutants
(H47D and C159R) template-based protein structure models were determined using
RaptorX web server (112). Red dots represent the aa present in the catalytic triad (H47,
D83, and C159), or the point mutations H47D or C159R introduced in SVA 3Cpro. (B)
Western blot analysis of H1299- cells expressing SVA 3Cpro showing that mutations in the
catalytic triad of the protease impairs its pro-apoptotic function. Protein extracts were
analyzed by western blot using antibodies specific for N-terminus NF-κB-p65, cleaved
Caspase 3, Flag-tag, and β-actin as loading protein control. The results are representative
of three independent experiments. (C) Luciferase assay showing that SVA 3Cpro catalytic
triad is important for its inhibitory effect on NF-κB-p65 transcriptional activity. H1299
cells were transfected with NF-κB-luciferase reporter plasmids and either wild type or
mutant 3C-expressing plasmids. At 12 h post-transfection cells were stimulated with TNFα for 12 h, and luciferase activity determined. Firefly luciferase activity was normalized to
the renilla luciferase activity. The results were expressed as relative fold changes in
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luciferase activity (**p < 0.05 and ***p < 0.01, compared to BAP-expressing cells treated
with TNF-α). Results shown represent the average of five independent experiments. Error
bars represent SEM. Western blots showing expression of BAP, wild type 3Cpro, 3C H47D,
and 3C C159R in samples examined by luciferase assays (bottom panel).
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Fig 15. Cleavage of NF-κB-p65 is mediated by caspases and not by the direct action of
SVA 3Cpro. (A) Schematic representation of NF-κB-p65 protein depicting predicted
cleavage sites for Casp-3/-6 (123) and/or SVA 3Cpro in the TAD. Western blot analysis of
H1299 cells expressing wild type or mutant NF-κB-p65 proteins containing aa
substitutions on SVA 3C predicted cleavage sites (B), caspase predicted cleavage sites (C),
or double SVA 3Cpro and caspase predicted cleavage sites (D). (E) Western blot to assess
cleavage of NF-κB-p65 in SVA 3Cpro-expressing cells in the presence or absence of
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caspase inhibitor Z-VAD-FMK. Blots in (B–E) were probed with antibodies indicated on
the left.
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Fig 16. Overexpression of NF-κB-p65 suppresses SVA-induced apoptosis and decreases
SVA yields. (A) Flow cytometry analysis of STu cells showing that transient expression
of NF-κB-p65 decreases apoptosis induced by SVA infection. Cells were stained with
CellEvent™ Caspase-3/7 Green Flow Cytometry Assay kit. The flow cytometry data were
acquired with an Attune NxT flow cytometer and analyzed using FlowJo software. The
results were expressed as percent of cells with active Casp-3/-7. Error bars represent SEM;
**p < 0.05 compared to mock-infected cells; Sidak's multiple comparison test. (B), (C)
Replication kinetics of SVA in STu (B) or H1299 cells (C) transiently expressing NF-κBp65. Cells were infected and harvested at indicated time points and virus titers determined
by the Spearman and Karber's method and expressed as log10 tissue culture infections dose
50 (TCID50) per milliliter. The results represent the average of three independent
experiments. Error bars represent SEM (**p < 0.05, ***p < 0.01; comparisons between
each time point, Students' t-test).
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Fig 17. Induction of apoptosis late in SVA infection is important for virus release and/or
spread from infected cells. Multiple-step growth curves in STu (A) or H1299 (B) cells
(MOI = 0.1), and single step growth curve STu (C) cells (MOI = 5) treated or not with ZVAD-FMK, a pan-caspase inhibitor. Cells and supernatants were harvested separately at
the indicated time points and subjected to virus titration. The virus titers were determined
by the Spearman and Karber's method and expressed as log10 tissue culture infections dose
50 (TCID50) per milliliter. Results represent the average of three independent experiments.
Error bars represent SEM **p < 0.05, ***p < 0.01; comparisons between each time point
in the multiple-step growth curve; and ***p < 0.01; comparisons between the time point
in the single-step growth curve. (D) Plaque assay in STu cells treated or not with Z-VADFMK showing reduced viral spread in cells in which apoptosis is inhibited. In the right
panel, the graphic represents SVA plaque forming unit area of cells treated or not with ZVAD-FMK (10−6 dilution). Plaque areas were determined with ImageJ software. Error
bars represent SEM (***p < 0.01; comparisons between treatments, Multiple t-tests).
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CONCLUSIONS

The overall goal of this study was to investigate the pathogenicity of a contemporary
and a historical strain of Senecavirus A (SVA) and to improve our understanding of the
interactions between SVA and the host death cell pathway. Below are the conclusions from
our studies:
1. Both SVA strains, SVV 001 and SD15-26 can infect pigs. Interestingly, while SVA
SD15-26 infection results in characteristic clinical signs and vesicular lesions, SVA
SVV 001 did not cause overt clinical disease.
2. Levels of viremia detected in SVA SD15-26 inoculated animals are significantly
higher than those detected in SVA SVV 001-inoculated animals.
3. Both SVA strains, SVV 001 and SD15-26, induce similar levels of virus shedding
in oral secretions and feces. However, there are differences in levels of virus
shedding in nasal secretions, with SVV 001-inoculated animals shedding lower
amounts of virus than SD15-26-inoculated animals.
4. The historical SVV 001 strain is attenuated in pigs while SVA SD15-26 is virulent.
5. Senecavirus A strains SVV 001 and SD15-26 have cross-neutralizing antibody and
cross-reactive T cell responses.
6. Senecavirus A infection induces apoptosis late during infection in vitro and in in
vivo.
7. The proteolytic activity of SVA 3Cpro is essential for induction of apoptosis.
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8. Apoptosis might facilitate virus release and/or spread from infected cells since
lower viral yields are detected in infected cells when apoptosis is suppressed.

Fig 18. Model of Apoptosis induction by SVA. Early during infection, Senecavirus A activates the
NF-κB pathway, inducing the expression of pro-inflammatory and pro-survival genes. At late
times post-infection, the apoptotic pathway is induced and there is activation of caspases 3/7. The
activated caspases cleave NF-κB-p65, inhibiting the NF-κB pathway, and this way, avoiding the
expression of pro-survival genes (red lines).
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